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ABSTRACT 
 
Elizabeth R. W. Knight:  Immune Molecules Regulate Medulloblastoma  
and Neuronal Apoptosis  
  (Under the direction of Mohanish Deshmukh) 
While the brain has long been considered an immunoprivileged region, recent 
research reveals that immune genes play important roles in neurons and the nervous 
system.  Neurons not only express immune genes but these genes can serve immune or 
neuron-specific functions.  Additionally, cytokines produced by immune cells can influence 
neuronal characteristics and survival.  In this work, I investigated the role of an immune 
cytokine, interferon-gamma (IFN-γ), on neuronal apoptosis and the role of an immune gene, 
ASC (Apoptosis-associated speck-like protein containing a caspase recruitment domain), in 
cancer of the cerebellum.      
While IFN-γ induces apoptosis in many cell types to limit the spread of infection, 
here we show that it protects sympathetic neurons from death with NGF deprivation or 
pan-kinase inhibition.  Specifically, we determined that IFN-γ inhibited apoptosis at the 
point of mitochondrial permeabilization, yet did not induce expression of a number of 
proapoptotic genes in sympathetic neurons that are upregulated in other cell types.  The 
ability of IFN-γ to promote sympathetic neuronal survival while inducing pro-death 
pathways in pathogens is likely a physiologically important mechanism which could ensure 
the long-term survival of these neurons during critical situations of infection.   
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We also examined the function of another immune gene, ASC, in the context of 
brain development and medulloblastoma, the most common malignant pediatric brain 
cancer.   ASC exerts pro-death effects in several cell types, is silenced in many cancers, and 
acts as a tumor suppressor in colon cancer.  Here, we present the unexpected findings that 
ASC deficiency robustly suppressed tumor incidence, delayed age of tumor onset, reduced 
premalignant lesion size, decreased EGL (external granule layer) proliferation, and increased 
TGF-β pathway expression and signaling in a mouse model of medulloblastoma.  These 
results identify a critical function of ASC in driving proliferation and tumorigenesis in this 
medulloblastoma model.  Therapies targeting ASC may be a promising strategy for 
preventing tumor progression of this challenging disease.  Together, these studies illustrate 
the ability of immune genes and signals to exert powerful effects on neuronal apoptosis and 
on a cancer of the nervous system.   
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CHAPTER I:  INTRODUCTION 
 
1.1  Apoptosis Overview 
Introduction 
 Cells can die by one of several mechanisms: apoptosis, pyroptosis, autophagy, or 
necrosis.  In apoptosis, the cell degrades its contents via cysteine proteases and 
compartmentalizes its fragments into apoptotic bodies to be engulfed by phagocytic cells.  
Thus apoptosis is an orderly way for a cell to die, leaving no trace behind.  Apoptosis is 
required for normal development, maintaining homeostasis, and preventing tumors and 
autoimmune diseases (Fink and Cookson, 2005; Taylor et al., 2008; Duprez et al., 2009).   
Pyroptosis, the newly discovered inflammatory cell death in immune cells is caused 
by the inflammasome complex activation of cysteine protease caspase-1, resulting in the 
cell lysing, spilling its contents into the milieu.  Released cellular cytokines activate the 
immune system to respond to the alarm, recruiting immune cells to the site of damage, 
where they can either promote healing or further destruction.  Pyroptosis is important for 
limiting infection and evoking immune response to pathogen and danger signals (Fink and 
Cookson, 2005; Duprez et al., 2009).   
 Autophagy, an intracellular catabolic mechanism that recycles cellular components 
inside autophagic vacuoles, can promote cell survival but can also induce cell death.  
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Autophagy-induced cell death is implicated in the demise of salivary gland cells during 
Drosophila metamorphosis (Fink and Cookson, 2005; Duprez et al., 2009). 
 Necrosis has been the catch-all phrase for uncontrolled, passive cell death involving 
caspase-1-independent cell lysis.  Necrosis is considered a back-up cell death mechanism 
when other types of cell death are blocked.  For instance, when death receptors are 
activated but apoptosis is blocked by caspases inhibition, a necrosis pathway involving RIP1 
(receptor interacting protein kinase -1) called necroptosis ensues.  Necrosis also results 
following TLR (toll-like receptors) or RLR (RIG-I-like receptors) activation by pathogen- or 
danger-associated signals and occurs in pathological conditions such as myocardial 
infarction, stroke, or traumatic brain injury.  Thus, cells can die by one of several 
mechanisms, characterized by environmental signal, biochemical pathways, and 
morphology (Fink and Cookson, 2005; Duprez et al., 2009).   
 
History of apoptosis 
 Apoptosis was first described in 1842 in the notochord of tadpoles by Carl Vogt, 
followed by extensive discoveries in chondrocytes, neurons, and other cell types (Clarke and 
Clarke, 1996).  Apoptosis was coined in 1972 by Kerr, Wyllie and Currie for the Greek 
meaning “falling off” of leaves from trees and was characterized in several human and rat 
tissues as an active, controlled cell deletion, with cells breaking apart into membrane-bound 
fragments which are then phagocytosed (Kerr et al., 1972).  The absence of cellular debris 
following cell death is a hallmark of apoptosis which allows a quiet death that does not elicit 
an immune response (Danial and Korsmeyer, 2004).  In 1976, John E. Sulston published his 
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findings on the programmed death of cells in C. elegans, demonstrating that cells 
reproducibly die during development.  Ellis and Horvitz then published in 1986 their findings 
in C. elegans of the first known genes required for apoptosis, ced-3 and ced-4 (Ellis and 
Horvitz, 1986).  Since these seminal discoveries, much progress has been made to elucidate 
the apoptotic machinery and mechanisms in varied organisms and cell types.   
 
Physiological functions of apoptosis 
Apoptosis was first discovered as a developmental process, and is required for 
normal organism development including organogenesis and vestigial organ removal, tissue 
remodeling including interdigital web removal (Milligan et al., 1995; Sharma et al., 2009), 
and death of neurons in the immature nervous system (Davies, 2003) (Figure 1.1).  
Apoptosis is also instrumental in maintaining homeostasis, for example by executing faulty 
or self-reactive immune cells (Marsden and Strasser, 2003), eliminating cells with a high 
turnover rate (e.g. red blood cells which die at a rate of 3000 cells per second) (Erwig and 
Henson, 2007), and post-development tissue remodeling, such as during mammary gland 
involution which restores mammary epithelial cells to pre-pregnancy number (Erwig and 
Henson, 2007).  Through the elimination of cells in the adult organism, apoptosis is able to 
balance the number of cells created to maintain homeostasis (Vaux and Korsmeyer, 1999).   
In addition to regulating development and homeostasis, apoptosis can either 
prevent or exacerbate various diseases (Fadeel and Orrenius, 2005).  Human embryonic 
stem cells exposed to DNA damage undergo rapid apoptosis, thereby eliminating chance of 
propagating mutated cells during embryogenesis (Dumitru et al., 2012).  Likewise, epithelial 
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cells undergo apoptosis following DNA damage (Green and Evan, 2002).  Apoptosis of cells 
infected with virus or bacteria limits the spread of infection (Dafny and Yang, 2005; Maher 
et al., 2007). Finally, immune cells induce apoptosis in tumor cells to block cancer 
development (Wang and El-Deiry, 2003).  Thus, apoptosis eliminates infected, 
dysfunctional, or damaged cells to promote the health of the organism (Carson and Ribeiro, 
1993). 
When apoptosis does not occur normally, cells that have accumulated mutations 
may proliferate uncontrollably, becoming tumor cells.  If these tumor cells escape apoptosis 
by evading immune surveillance, they may develop into cancers.  Furthermore, some 
mutations can suppress the apoptotic pathway or enhance survival pathways, thereby 
rendering the tumor cell resistant to external apoptotic signals (Martin, 2003; Yu and Zhang, 
2003; Wright and Deshmukh, 2006).  Inadequate apoptosis of immune cells can also cause 
systemic autoimmunity (Siegel et al., 2000). 
While insufficient apoptosis may lead to pathology, increased apoptosis can also 
occur in disease states.  Reperfusion following an ischemic event induces apoptosis in 
cardiac or brain tissue (Honda and Ping, 2006; Jung et al., 2010).  Also, many 
neurodegenerative diseases are characterized by apoptosis of mature neurons, which 
normally live for the lifetime of the organism (Honig and Rosenberg, 2000; Gorman, 2008; 
Nakamura et al., 2012). Neurotoxins released in neurodegenerative disease states induce 
apoptosis in neurons (Gorman, 2008).  Blocking apoptosis can reduce the deleterious effects 
of diseases.  Repressing apoptosis in models of traumatic brain injury, stroke, or ALS 
(amyotrophic lateral sclerosis) reduces cell death and improves clinical outcome (Hara et al., 
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1997; Hara et al., 1997; Kostic et al., 1997; Yakovlev et al., 1997).  Furthermore, inhibiting 
apoptosis in telencephalic neurons exposed to fibrillar amyloid beta, a hallmark of 
Alzheimer disease, prevented neuron death (Selznick et al., 2000).  Thus, apoptosis can be 
both a cause and a consequence in many pathologies.   
 
Apoptotic mechanisms 
In 1986, Ellis and Horvitz demonstrated a requirement for ced-3 and ced-4 genes in 
normal developmental apoptosis in C. elegans (Ellis and Horvitz, 1986).  The Horvitz lab later 
discovered the requirement of ced-9 “to protect cells that normally survive from undergoing 
programmed cell death” (Hengartner and Horvitz, 1994).  Ced-9 prevents Ced-4 from 
activating Ced-3 to subsequently cause apoptosis (Hengartner et al., 1992; Danial and 
Korsmeyer, 2004).  The mammalian homologs of the nematode genes were determined to 
be BCL-2 (B-cell lymphoma 2; Ced-9), Caspase-3 (Ced-3), and Apaf-1 (Ced-4) (Danial and 
Korsmeyer, 2004).  Sequence homology analysis to Ced-3 led to the discovery of an entire 
family of caspases, inactive zymogens that, upon activation, become cysteine proteases that 
cleave aspartic acid motifs.  Apoptotic caspases, including caspases-8, -9, and -3, degrade a 
multitude of cellular substrates to cause the apoptotic morphology characterized by cell 
shrinkage, membrane blebbing, DNA fragmentation, and chromatin condensation (Danial 
and Korsmeyer, 2004). 
After several decades of research since the discovery of the nematode genes, the 
major players in the apoptotic pathway have been elucidated.  Apoptosis can occur due to 
extrinsic or intrinsic signals.  Extrinsic signals such as Fas, TRAIL, or TNFα bind to their 
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respective receptors, inducing activation of the extrinsic apoptotic pathway.   Ligand-
receptor binding activates caspase-8, which cleaves Bid into tBid, which translocates to the 
mitochondria to cause mitochondrial permeabilization and cytochrome c release (Ozoren 
and El-Deiry, 2003; Riedl and Shi, 2004).  Since our lab studies intrinsic apoptosis, this 
section will focus on the intrinsic, or mitochondrial, apoptotic pathway.  
In intrinsic apoptosis, signals from DNA damage, trophic factor deprivation, ER 
stress, or other insults trigger the activation of pro-apoptotic BH3-only proteins through 
upregulation or phosphorylation (Vaux and Korsmeyer, 1999).  Pro-apoptotic BH3-only 
proteins are in the Bcl-2 family and contain a single BH3 (Bcl-2 homology -3) domain.  
Examples of BH3-only proteins are Bim, Bad, Bid, Puma, Noxa, Bmf, and DP5 (Chao and 
Korsmeyer, 1998).  Anti-apoptotic Bcl-2 family members, Bcl-2, Bcl-XL, and Bcl-w contain BH 
domains 1-4 and are localized at the mitochondrial membrane where they prevent 
mitochondrial permeabilization by associating with pro-apoptotic proteins Bax and Bak 
(Cory and Adams, 2002).  Bax and Bak are Bcl-2 family members that contain BH domains 1-
3 (Danial and Korsmeyer, 2004).  BH-3 only proteins, such as Bim and Bid, can be 
“activators" by binding and activating Bax/Bak directly through induction of an allosteric 
conformational change (Figure 1.2).  Other BH-3 only proteins, including Bad and BMF, are 
“sensitizers” that compete for binding to anti-apoptotic Bcl-2 and Bcl-XL, preventing their 
suppression of Bax/Bak (Letai et al., 2002; Deng et al., 2007; Ren et al., 2010).  When 
released from repression by Bcl-2 and Bcl-XL, Bax and Bak undergo a conformational 
change, inserting and oligomerizing in the mitochondrial membrane, forming a pore in the 
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outer membrane that then releases cytochrome c, Smac, AIF, and other mitochondrial 
proteins (Danial and Korsmeyer, 2004; Chipuk and Green, 2008).       
In the mitochondria, cytochrome c transfers electrons as an essential part of the 
electron transport chain.  When cytochrome c is released from the mitochondria into the 
cytosol, it binds to the WD40 repeat domain of Apaf-1 (Figure 1.3).  Binding of cytochrome c 
to Apaf-1 in the presence of dATP releases the autoinhibition of WD40 and induces a 
conformational change which exposes the CARD (caspase activation and recruitment 
domain) of Apaf-1.  The CARD domain recruits procaspase-9 via homotypic CARD binding.  
This tripartite structure composed of cytochrome c, Apaf-1, and procaspase-9 oligomerizes 
as a heptameric apoptosome, a ~700 kDa structure that activates procaspase-9 through 
autocatalytic cleavage (Srinivasula et al., 1998; Acehan et al., 2002; Cain et al., 2002; Riedl et 
al., 2005).   
Caspase-9, once activated by the apoptosome, induces a cascade of caspase 
activation.  Caspase-9 activates caspase-3/7 and indirectly activates caspase-6.  Caspase 3 
then can activate caspase-2/6, which then activate caspase-8/10.  Caspase 3 also can 
activate caspase-8/9, escalating a positive feedback loop of caspase activating amplification 
(Creagh et al., 2003; Riedl and Shi, 2004).  
Caspases are cysteine proteases that exist as zymogens until activated.  While 
individual caspases can have many substrates, each caspase cleaves a specific substrate 
sequence of four residues amino-terminal to an aspartic acid motif (Hengartner, 2000).  
Initiator caspases include caspase-9, -8, -2 and -10, which are activated directly by the 
apoptotic machinery to initiate the caspase cascade (Figure 1.4).  Initiator caspases have a 
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CARD or DED (death effector domain) N-terminal prodomain that allows for homotypic 
protein interactions (Riedl and Shi, 2004; Boucher and Denault, 2012).  Initiator caspases 
activate effector caspases, such as caspase-3, -6 and -7, which cleave an array of substrates 
to produce the morphology of apoptosis- membrane blebbing, DNA fragmentation, cell 
shrinkage, and chromatin condensation (Thornberry and Lazebnik, 1998; Riedl and Shi, 
2004).   
Interestingly, caspases can have nonapoptotic functions, for instance caspase-3 
plays a role in differentiation of erythroblasts and inhibition of B-cell proliferation (Nhan et 
al., 2006; Lamkanfi et al., 2007).  Furthermore, additional caspases exist that do not play a 
role in apoptosis.  Caspase-1, originally known as ICE (interleukin-1β converting enzyme) 
was first discovered as the homolog to the C. elegans gene ced-3, which promoted 
apoptosis in nematodes, yet caspase-1 has been determined to have a role not in apoptosis, 
but in inflammation (Riedl and Shi, 2004).  Likewise, caspase-4, -5, (human) and -11 (mouse) 
are also activated primarily in inflammatory responses (Creagh et al., 2003).  Inflammatory 
caspases have an N-terminal CARD or DED prodomain for homotypic protein binding (Figure 
1.4) (Creagh et al., 2003; Martinon and Tschopp, 2007). 
Following apoptosome formation and initiation of the caspase activation cascade, 
apoptotic caspases can be blocked by inhibitors of apoptosis proteins (IAPs).  Eight 
mammalian IAPs have been discovered thus far and include XIAP (X-linked IAP), NAIP 
(neuronal apoptosis inhibitory protein), c-IAP1, c-IAP2, ML-IAP (melanoma IAP)/Livin, 
Survivin, ILP2 (IAP-like protein-2), and Bruce.  IAPs contain a baculoviral IAP repeat (BIR) 
domain and can block caspases by binding directly or targeting them to the ubiquitin-
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proteasome pathway for degradation.  XIAP is the only mammalian IAP that has been 
shown to bind caspases directly.  XIAP mediates caspase inhibition by binding a tetrapeptide 
motif on active caspases directly through one of its BIR domains and sterically blocking 
substrates from binding with the active caspases.  Research also suggests that XIAP may 
ubiquitinate caspases through its C-terminal RING finger domain, which has E3 ubiquitin 
ligase activity (Riedl and Shi, 2004; Eckelman et al., 2006). 
Inhibitors of apoptosis proteins themselves have an inhibitor: Smac/DIABLO.  Smac is 
a mitochondrial protein that is released with cytochrome c into the cytosol following 
mitochondrial permeabilization.  The IAP-binding tetrapeptide motif in Smac competes with 
caspases for binding to the BIR domain of IAPs, allowing both initiator and effector caspases 
to remain unimpeded (Hengartner, 2000; Riedl and Shi, 2004). 
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1.2  Neuronal Apoptosis 
Introduction 
Sensory neurons were first discovered to undergo elimination in 1889, followed by a 
discovery of spinal ganglion cell death in chick embryos in 1906 (Clarke and Clarke, 1996).  
Since then, scientists have discovered that apoptosis occurs throughout the nervous 
system- in spinal cord, the retina, cerebellum, cortex, brain stem, and sensory and 
autonomic ganglia (Buss et al., 2006).  The importance of apoptosis for normal nervous 
system development is revealed upon removal of any single gene required for apoptosis.  
Apaf-1, caspase-9, or caspase-3 knockout animals have enlarged brains and a high incidence 
of embryonic lethality (Kuida et al., 1996; Cecconi et al., 1998; Kuida et al., 1998; Buss et al., 
2006).  Between 20 and 80% of all neurons that are born undergo cell death during 
development (Oppenheim, 1991).  Deletion of neurons may correct errors in cell migration, 
axonal pathfinding, or target innervation, and thus refine functional nervous system 
circuitry (Buss et al., 2006).  Furthermore, apoptosis ensures that neurons that are 
outcompeted for limited trophic factors via target innervation are eliminated (Buss et al., 
2006).  In summary, neuronal apoptosis is required for proper wiring and development of 
the nervous system. 
 
Sympathetic neurons 
In the sympathetic nervous system, superior cervical ganglia (SCG) innervate the 
eye, and salivary and tear glands (Vinken and Bruyn, 1999).  Sympathetic neurons of the 
SCG extend axons to their targets which secrete neurotrophic growth factor (NGF).  NGF 
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was the first neurotrophic factor to be discovered and is required by sympathetic neurons 
for survival (Thoenen and Edgar, 1985).  When neutralizing antibodies block this single 
growth factor in vivo, 99 % of the sympathetic neurons in young mouse SCGs are ablated 
(Levi-Montalcini and Booker, 1960).   
Sympathetic neurons can be studied in vitro as well since primary sympathetic 
neurons from rat or mouse SCG can be dissociated and maintained in very pure cultures.  
NGF deprivation causes virtually all neurons to undergo apoptosis within 48 hours, with the 
classic features of DNA fragmentation, chromatin condensation, neurite degeneration, and 
membrane blebbing.  Because these cells are able to be maintained in pure cultures and 
also undergo apoptosis in response to one signal, sympathetic neurons are an ideal model 
with which to study the apoptotic pathway (Deshmukh and Johnson, 1997; Rubin, 1997).   
During development, immature sympathetic neurons extend their axons to their 
NGF-secreting targets.  Sympathetic neurons either fail to reach their target, thus 
undergoing NGF-deprivation-induced apoptosis, or the neurons innervate their targets and 
mature, losing sensitivity to NGF deprivation with maturation around P11 (Glebova and 
Ginty, 2005).  The sympathetic neuron experiments presented in this dissertation were 
conducted in young (P5) neurons, which undergo apoptosis in response to NGF deprivation. 
The presence of NGF stimulates activation of pro-survival pathways, while the 
absence of NGF triggers an active pro-apoptotic response (Figure 1.5).  NGF phosphorylates 
the tyrosine kinase receptor, TrkA on sympathetic neuron axon terminals, activating the PI-
3-kinase/Akt pathway which promotes cell survival (Brunet et al., 2001).  In the absence of 
NGF, an active signaling pathway requiring transcription and translation executes apoptosis 
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(Martin et al., 1988; Deshmukh and Johnson, 1997).  NGF deprivation triggers activation of 
Rho GTPase Cdc42, which leads to activation of the MLK (mixed lineage kinase) and MAPK 
(mitogen-activated protein kinase) pathways.  MKK4/MKK7 activate JNKs including JNK3, 
which phosphorylate c-Jun at serine residue 63 (Xia, Dickens et al. 1995; Eilers, Whitfield et 
al. 1998; Maroney, Finn et al. 1999; Ham, Eilers et al. 2000; Bruckner, Tammariello et al. 
2001).  Ser63 phosphorylation activates transcription factor activity of c-Jun, which induces 
transcription of c-Jun and BH3-only genes including Bim, DP5, Puma, and Bmf (Putcha, 
Moulder et al. 2001; Imaizumi, Benito et al. 2004; Kole, Swahari et al. 2011; Kristiansen, 
Menghi et al. 2011).  Upregulation of the BH3-only proteins is required to block Bcl-2 and 
Bcl-XL and promote Bax activation.  Active Bax oligomerizes and forms a pore in the 
mitochondrial outer membrane, releasing cytochrome c into the cytosol, as described 
above (see previous section).  Cytochrome c binds to Apaf-1, initiating apoptosome 
formation and subsequent caspase activation.  Blocking any step of this pathway inhibits 
apoptosis in NGF-deprived sympathetic neurons.  Thus, NGF deprivation executes 
mitochondrial permeabilization and exploits the intrinsic apoptotic pathway in sympathetic 
neurons. 
 
Apoptosis inhibition in sympathetic neurons 
Sympathetic neurons have several mechanisms by which they can suppress key 
players of the apoptotic pathway.  Firstly, neurons have a truncated form of Bak, N-Bak, 
which lacks BH3 domains necessary for pro-apoptotic activity.  Thus, neurons rely solely on 
Bax for mitochondrial permeabilization (Deckwerth et al., 1998) and loss of Bak expression 
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does not alter neuronal death with NGF deprivation (Putcha et al., 2002; Sun et al., 2003; 
Uo et al., 2005).  Furthermore, mature neurons upregulate miR-29, which blocks translation 
of BH3-only genes in these cells (Kole et al., 2011).  MiR-29-mediated restriction of BH3-only 
gene expression prevents Bax activation, thus providing another obstacle to apoptosis (Kole 
et al., 2011).    
Sympathetic neurons also restrict apoptosis at the point of cytochrome c release.   In 
healthy young neurons, cytochrome c is inactivated by the reduced environment.  Thus tBid 
microinjection induces apoptosis in MEFs (mouse embryonic fibroblasts) but no death in 
sympathetic neurons (Vaughn and Deshmukh, 2008).  NGF deprivation in neurons generates 
reactive oxygen species which oxidize the cytosol, allowing cytochrome c to become 
activated and cause programmed cell death (Vaughn and Deshmukh, 2008).  Autophagy-
independent degradation may be another mechanism to suppress cytochrome c (Davidescu 
et al., 2012).   
Once functional cytochrome c is released, Apaf-1 binding is required for apoptosome 
formation.  Apaf-1 protein levels have been shown to decrease with development (P3 vs 
E16) and are further reduced with maturation (Wright et al., 2004) in sympathetic neurons 
via chromatin repression (Wright et al., 2007).  Apaf-1 levels are also decreased in PC12 
cells with neuronal-like differentiation (Wright et al., 2004).  Apaf-1 expression is required 
for apoptosis in sympathetic neurons (Wright et al., 2007) and some types of apoptotic 
insults, such as DNA damage, upregulate Apaf-1 mRNA and protein to promote apoptosis 
(Vaughn and Deshmukh, 2007). 
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Following apoptosome formation, XIAP serves as a formidable opponent to caspase 
activation in sympathetic neurons.  Caspase-9 and -3 are required for sympathetic neuron 
apoptosis with NGF deprivation (Wright et al., 2007) and are rendered incompetent by XIAP 
(Vaughn and Deshmukh, 2008).  Endogenous Smac released from the mitochondria is 
insufficient to block XIAP in sympathetic neurons (Vaughn and Deshmukh, 2008), yet 
microinjection of excess Smac along with cytochrome c enables XIAP neutralization and 
death (Potts et al., 2003).  Thus, endogenous Smac does not serve as a brake to XIAP 
inhibition of caspases in sympathetic neurons.  To remove XIAP, neurons degrade XIAP 
mRNA and protein in response to NGF deprivation, enabling these cells to undergo 
apoptosis (Potts et al., 2003; Vaughn and Deshmukh, 2007).  Thus, even at the level of 
caspase activation, sympathetic neurons have developed an important guardian of cell 
survival, XIAP, to constrain apoptosis. 
By utilizing these hurdles to inhibit apoptosis at every step of the pathway, 
sympathetic neurons ensure survival in instances of slight damage, cytochrome c release, or 
caspase activation.  These brakes prevent accidental initiation of apoptosis yet enable cell 
death warranted by significant insult.  This remarkable resistance to apoptosis ensures the 
survival of these cells which must persist for the lifetime of the organism. 
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1.3  Medulloblastoma 
Medulloblastoma (MB), a tumor of cerebellar progenitors, is the most common 
malignant brain cancer in children (Hatten and Roussel, 2011), with 20% of pediatric central 
nervous system tumors, or 540 cases  (0.6 per 100,000 children 0-19 years old) in the U.S. 
diagnosed each year (Polkinghorn and Tarbell, 2007; Lau et al., 2012).  Symptoms of 
medulloblastoma include morning vomiting, ataxia, and headaches.  30% of childhood cases 
show cerebrospinal fluid metastasis at diagnosis (Polkinghorn and Tarbell, 2007).  5 year 
overall survival rates are approximately 60%, yet side effects from radiation treatment 
include cognitive impairment (reduction of up to 30 IQ points), psychiatric illness, bone 
growth retardation, hearing loss, and endocrine disruption (Polkinghorn and Tarbell, 2007; 
Ellison, 2010; Roussel and Hatten, 2011).   
In the past, MBs have been classified into histological categories including classic, 
desmoplastic, large cell/anaplastic (LC/A), and medulloblastoma with extensive nodularity 
(MBEN) (Gilbertson and Ellison, 2008; Roussel and Hatten, 2011).  Recent research, 
however, has used molecular characteristics (mutations, deletions, amplifications, etc.) to 
categorize tumors based on the specific pathway altered, including SHH (Sonic Hedgehog), 
WNT/β-catenin, MYC, Notch, BMP, and/or TGF-β signaling pathways (Marino, 2005; 
Polkinghorn and Tarbell, 2007; Ellison, 2010; Gibson et al., 2010; Cho et al., 2011; Hatten 
and Roussel, 2011; Roussel and Hatten, 2011; Northcott et al., 2012).  Amplification of the 
SHH pathway is the best characterized of these subgroups, with 25% of MBs having 
mutations in Patched, Sufu (Suppressor of Fused Homolog), Smoothened, or other genes in 
the pathway (Marino, 2005; Gibson et al., 2010).  During normal development, activation of 
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the SHH pathway stimulates proliferation of cerebellar granule neuron progenitors (CGNPs), 
which undergo rapid division in the external granule layer (EGL), then differentiate and 
migrate to the internal granule layer (IGL) during the early postnatal period (Hatten and 
Heintz, 1995).  In medulloblastoma, overactive SHH signaling induces CyclinD1 and CyclinD2 
expression which promote the hyperproliferation of CGNPs.  Mutations that activate SHH 
signaling cause predisposition to medulloblastoma in humans with Gorlin Syndrome and in 
genetically engineered mouse models (Polkinghorn and Tarbell, 2007; Hatten and Roussel, 
2011).  These models, which operate through either Patched deletion or insertion of 
constitutively active alleles of Smoothened, consistently implicate CGNPs as the cells of 
origin for SHH-driven medulloblastoma (Hallahan, Pritchard et al. 2004; Yang, Ellis et al. 
2008).   
In conclusion, while advances in treatment have increased the survival of 
medulloblastoma patients, mortality remains significantly high (30%) and debilitating side 
effects result from current treatment regimens (Polkinghorn and Tarbell, 2007; Jones et al., 
2012).  Thus, advancing the understanding of the genetic components of medulloblastoma 
tumorigenesis is needed to develop improved targeted therapies. 
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1.4  Figures and Legends 
 
Figure 1.1.  Syndactylyl is caused by insufficient apoptosis 
Apoptosis is required for normal development, including cell death of interdigital webbing. 
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Figure 1.1 
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Figure 1.2.  The Bcl-2 family 
The Bcl-2 family is comprised of pro-apoptotic Bax and Bak, anti-apoptotic Bcl-2 and Bcl-XL, 
and sensitizer or activator BH3-only proteins.   
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Figure 1.2 
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Figure 1.3.  Formation of the apoptosome complex 
Cytochrome c binds to the WD40 domain of Apaf-1, inducing a conformational change that 
releases auto-inhibition and recruits procaspase-9 to the CARD domain of Apaf-1. 
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Figure 1.3 
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Figure 1.4.  The Caspase family 
The caspases were discovered by sequence homology analysis with nematode gene ced-3.  
Caspases have a primary role as initiators or executioners of apoptosis, or in inflammation.  
Executioner proteins lack an N-terminal protein interaction domain such as CARD or DED.  
The family of murine caspases is below.   
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Figure 1.4 
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Figure 1.5.  The NGF deprivation apoptotic pathway 
NGF absence activates Rho GTPase Cdc42, which activates MLK and MAPK pathways, 
phosphorylating JNK.  JNK phosphorylates c-Jun, which upregulates the BH3-only genes.  
BH3-only genes block Bcl-2 and Bcl-XL and activate Bax.  Bax oligomerizes at the 
mitochondrial membrane, forming a pore which releases cytochrome c into the cytosol.  
Cytochrome c binds the WD40 domain of Apaf-1, which induces apoptosome formation 
with procaspase-9, activating caspase-9.  If caspases escape XIAP inhibition, caspase-9 
initiates a positive feedback loop of caspase activation. 
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Figure 1.5 
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CHAPTER II:  INTERFERON-GAMMA PROTECTS SYMPATHETIC NEURONS FROM  
APOPTOSIS AT THE POINT OF CYTOCHROME C RELEASE 
 
2.1  Overview 
While immune responses during nervous system injury and disease are well studied, 
exactly how primary neurons respond to immune signals is still largely unknown.  We find 
that primary sympathetic neurons respond unexpectedly to interferon-gamma (IFN-γ), a 
cytokine released by immune cells in response to infection.  While IFN-γ induces apoptosis 
in many cell types, it has the opposite effect on sympathetic neurons by protecting them 
from apoptotic stimuli.  We found that IFN-γ addition enabled sympathetic neurons to 
become resistant to nerve growth factor (NGF) deprivation- or pan-kinase inhibition-
induced apoptosis.  In investigating how IFN-γ modulates the apoptotic pathway, we 
discovered that c-Jun phosphorylation and Bim induction in response to NGF deprivation 
were unchanged with IFN-γ.  Downstream of the mitochondria, however, IFN-γ blocked 
cytochrome c release and caspase-3 activation in NGF-deprived neurons.  Microinjection of 
cytochrome c into XIAP-/- neurons revealed no difference in cell death with IFN-γ addition, 
demonstrating a role for IFN-γ at the point of mitochondria permeabilization.  These results 
identify Bax activation as the likely point at which IFN-γ acts to inhibit neuronal apoptosis.  
Finally, microarray analysis revealed that sympathetic neurons respond to IFN-γ by 
upregulating interferon-inducible genes and several pro-apoptotic genes.  Together, our 
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results show that IFN-γ is not only incapable of inducing apoptosis in neurons but 
remarkably enables neurons to become resistant to apoptosis.  As sympathetic neurons 
become exposed to IFN-γ during infection or injury, the ability of IFN-γ to inhibit apoptosis 
in neurons is likely important for ensuring the long-term survival of neurons during 
situations of pathological stress.  
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2.2  Introduction 
Overview of Interferons 
A major mechanism of cellular host response to pathogenic infection is the secretion 
of interferons (IFNs).  IFNs are upregulated and released by cells to inhibit pathogen 
replication and regulate activation of immune cells.  In particular, IFNs are known to induce 
apoptosis of both infected cells and pathogens to limit the spread of infection (Dafny and 
Yang, 2005; Maher et al., 2007).  Additionally, IFNs modulate angiogenesis and regulate cell 
growth, proliferation, and differentiation (Chawla-Sarkar et al., 2003; Maher et al., 2007).  
IFNs also exert these functions during injury and in tumor suppression (Chawla-Sarkar et al., 
2003; Maher et al., 2007).  IFNs are classified into different subtypes where Type I IFNs (IFN-
α and IFN-β) are produced by almost all cell types, with hematopoietic cells being major 
producers of IFN-α and fibroblasts being the main source of IFN-β (Schroder et al., 2004; 
Maher et al., 2007).  Th1 lymphocytes and natural killer (NK) cells are the major source of 
Type II IFN, IFN-γ (Chawla-Sarkar et al., 2003; Schroder et al., 2004; Dafny and Yang, 2005; 
Maher et al., 2007).  Type III IFN, IFN-λ, was recently discovered through sequence 
homology analysis and is not well characterized (Maher et al., 2007). 
The signaling pathway for IFN production has been well characterized in the context 
of the immune system.  IRFs (IFN regulatory factors) induce interferon production in 
response to pathogen-associated molecular patterns or other signals (Maher et al., 2007).  
IFN-α/β bind IFNAR (IFN-α receptor) and IFN- γ binds to IFNGR (IFN-γ receptor), but both 
types phosphorylate and activate the JAK (Janus tyrosine kinase)/STAT (signal transducers 
and activators of transcription) pathway (Schroder et al., 2004).  STATs bind to ISRE (IFN-
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stimulated response element sequence in promoter) or GAS (gamma interferon-activated 
sequence) sequences to mediate the regulation of at least 300 interferon-stimulated genes 
(ISGs) (Dafny and Yang, 2005; Maher et al., 2007).  The activation of the JAK/STAT pathway 
mediates the antiproliferative, antiviral, and immunomodulatory functions of interferons 
(Maher et al., 2007).  Phosphorylation of JAK leads to downstream activation of the PI3K 
pathway (Akt, mTOR), insulin and IGF-1 receptor signaling, and also p38, JNK (c-Jun N-
terminal kinases) and ERK (extracellular signal regulated kinases) MAPKs (mitogen-activated 
protein kinases) (Kalvakolanu and Roy, 2005; Maher et al., 2007; Hervas-Stubbs et al., 
2011).  Interferon activation can also lead to NF-κB activation (Hervas-Stubbs et al., 2011). 
 
Interferons regulate apoptosis 
In addition to inhibiting translation and transcription in cells to suppress expression 
of viral genes and proteins, interferons also induce apoptosis of infected or surrounding 
cells through gene regulation in a variety of cell types to limit spread of infection.  Through 
upregulation of genes involved in the apoptotic pathway and other genes that induce cell 
death through unknown mechanisms (DAPs, IRFs, RIDs, RNaseL), the interferons induce 
apoptosis in many cell types including endothelial cells (Chawla-Sarkar et al., 2003), 
keratinocytes (Maher et al., 2007), hepatocytes (Barber, 2000; Chawla-Sarkar et al., 2003), 
oligodendrocytes (Baerwald and Popko, 1998), fibroblasts (Dijkmans et al., 1990), and many 
types of cancer cells (Barber, 2000; Becher et al., 2000; Chawla-Sarkar et al., 2003; Clemens, 
2003; Schroder et al., 2004; Pokrovskaja et al., 2005; Maher et al., 2007; Zhang et al., 2008; 
Das et al., 2009).  Additionally, interferons can also sensitize cells to apoptosis by viral 
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infection or apoptotic stimuli through upregulation of apoptotic genes (Choi et al., 1999; 
Sedger et al., 1999; Nishikawa et al., 2001; Chawla-Sarkar et al., 2003; Clemens, 2003; 
Maher et al., 2007; Gysemans et al., 2008).   
Although interferons are considered apoptosis-inducing cytokines (Chawla-Sarkar et 
al., 2003; Schroder et al., 2004) there is evidence that interferons may inhibit apoptosis in 
activated T cells and primary B cells (Barber, 2000; Clemens, 2003; Pokrovskaja et al., 2005).  
Mechanisms for an anti-apoptotic response include blocking cell cycle (p21 upregulation in 
macrophages (Barber, 2000; Chawla-Sarkar et al., 2003; Clemens, 2003), activation of NF-κB 
(Clemens, 2003; Hervas-Stubbs et al., 2011), PI3K activation (Clemens, 2003), or 
upregulation of ifi202b (interferon-inducible protein 202b), which modulates activity of 
multiple transcription factors (Koul et al., 1998; Clemens, 2003). 
 
Interferons in neuronal apoptosis 
While interferons overwhelmingly exert a pro-apoptotic effect on most cell types, 
there is evidence for a mixed outcome in neurons.  IFN-γ transgenic HSV-infected mice 
displayed reduced neuronal apoptosis than wild-type mice, while IFN-γ-/- mice exhibited 
greater neuronal death and exacerbated encephalitis and ataxia.  In both cases, increased 
IFN-γ signaling corresponded to increased neuronal expression of Bcl-2 and these effects 
were independent of viral replication and neuroinvasion (Geiger et al., 1994; Geiger et al., 
1995; Geiger et al., 1997).  Similarly, IFN-γ-/- mice infected with Borna disease virus (BDV) 
exhibited increased hippocampal neuronal apoptosis during CD8+ T cell responses than 
wild-type mice (Richter et al., 2009).  Other research shows that IFN-α/β sensitizes 
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fibroblasts, but not dorsal root ganglia (DRG) neurons to cell death by poly(I:C) (Yordy et al., 
2012).   
Conversely, other research indicates that interferons can induce apoptosis in 
neurons.  Type I IFN inhibited BDNF (brain-derived neurotrophic factor)-mediated survival 
and neurite outgrowth of primary mouse cortical neurons, which was associated with 
caspase activation and reduced TrkB, Akt, and ERK1/2 signaling (Dedoni et al., 2012).  In 
vitro, IFN-γ either induced apoptosis in motoneurons (Smith et al., 2009; Aebischer et al., 
2011) or had no effect (Mir et al., 2009), however in vivo, spinal cord motoneurons in 
untreated IFN-γ-/- mice were positive for apoptotic markers (TUNEL, active Casp3), unlike 
wild-type mice (Victorio et al., 2010).  Another study found that IFN-γ does not induce death 
of cortical, hippocampal, DRG, or striatal neurons but protects motoneurons from death 
induced by mutant SOD astrocyte media (Aebischer et al., 2011).  Thus, interferons’ effects 
on neuron survival can be protective, neutral, or deleterious and further research is needed 
to elucidate the role of interferons in neuronal apoptosis. 
 
Interferons and sympathetic neurons 
Sympathetic neurons of the peripheral nervous system may be particularly exposed 
to infectious microorganisms and immune cells (Rottenberg and Kristensson, 2002), as 
some pathogens first invade sensory nerves and spread to the brain via centripetal axonal 
transport (Rottenberg and Kristensson, 2002).  DRG (dorsal root ganglia) and SCG 
(sympathetic cervical ganglia) express interferon receptors and interferons protect 
peripheral neurons from viral and bacterial infection (Tsukamoto and Price, 1982; Chang et 
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al., 1990; Rottenberg and Kristensson, 2002; Burdeinick-Kerr et al., 2009; Mitchell et al., 
2012).  Additionally, Chang et al. found that rat sympathetic neurons exposed to IFN-γ are 
resistant to apoptosis induced by nerve growth factor (NGF) deprivation (Chang et al., 
1990).  In this study, we show that IFN-γ suppresses apoptosis in sympathetic neurons 
treated with nerve growth factor deprivation or pan-kinase inhibition.  Importantly, we 
report that IFN-γ acts at the point of mitochondrial permeabilization to suppress the 
intrinsic apoptotic pathway in NGF-deprived neurons.  Interestingly, IFN-γ exerts this 
protective effect on sympathetic neurons despite inducing the expression of several pro-
apoptotic genes.  These findings point to inhibition of Bax activation as the likely mechanism 
by which this immune cytokine inhibits sympathetic neuron apoptosis.  
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2.3  Methods 
 
Cell Culture:    
Primary sympathetic neurons were dissected from the superior cervical ganglia of 
P0-1 wild-type ICR or XIAP-deficient C57BL/6 mice, dissociated and maintained until P5 
equivalent, as previously described (Potts et al., 2003).  At P5-6, neurons were untreated or 
treated with NGF deprivation, pan-kinase inhibition with 100 nM staurosporine (STS), DNA 
damage with 20 μM etoposide, or ER stress with 2.5 μM tunicamycin (TUN).  NGF deprived 
neurons were washed three times and then maintained in NGF-deficient media with anti-
NGF neutralizing antibody.  Unless otherwise indicated, 500 U/ml IFN-γ was added 
simultaneously with apoptotic insult, with boiled IFN-γ serving as a negative control.   
 
Immunofluorescence:   
Neurons were fixed with 0.4 % paraformaldehyde at 12 hours for phospho-c-Jun, 24 
hours for cleaved caspase-3, or 48 hours for cytochrome c.  Pan-caspase inhibitor 25 μM Q-
VD-OPh (MP Biomedicals) was added during cytochrome c immunofluorescence 
experiments.  Immunofluorescence staining was performed as previously described 
(Deshmukh and Johnson, 1998).  Primary antibodies used were anti-cytochrome c 
(#556432, BD Biosciences; 1:100 dilution), anti-phospho-c-Jun-Ser63 (#9261, Cell Signaling; 
1:1000 dilution), and cleaved caspase-3 (1:100, Cell Sig.).  Secondary antibodies were Cy3 
(1:400) or Alexa 488 (1:1000)-conjugated antibodies (Jackson Immunoresearch Laboratories 
Inc.; 1:400 dilution).  Nuclei were counterstained with 4’6-diamino-2-phenylindole (DAPI) in 
mounting media (Vector Laboratories) or Hoechst 33258 (Molecular Probes).   
 35 
 
 
Western blot analysis:   
Mouse cerebella and tumors were homogenized in RIPA buffer and protein 
concentration was determined by Pierce BCA assay (ThermoScientific, Waltham, MA, USA).  
Immunoblotting was performed as previously described (Deshmukh et al., 2002) or by using 
a SNAP ID device (Millipore) per protocol.  Blots were probed with antibodies to Apaf-1 
(1:500, Alexis), XIAP (1:500, MBL), β-actin (Sigma, 1:10000), Bax (1:500, Santa Cruz Biotech), 
Bcl-XL (1:1000, Cell Sig.), Bim (1:1000, Cell Sig.), cleaved caspase-3 (1:500, Cell Sig.), 
procaspase-3 (1:1000,Stressgen), phospho-c-Jun (1:500, Cell Sig.), Puma (1:1000,Cell Sig.), 
alpha-tubulin (Sigma-Aldrich), and Smac (R&D).  Antibody conjugates were visualized by 
chemiluminescence (ECL; GE Healthcare, Buckinghamshire, UK). 
 
Microinjection:   
XIAP-/- sympathetic neurons were injected with (8 μg/μL) rhodamine-dextran (Sigma) 
with or without 15 mg/ml bovine cytochrome c as previously described (Potts et al., 2003).  
500 U/ml IFN-γ was added where indicated to plates 24 hours before injection.   
 
Quantitation of cell survival: 
Neuron survival was assessed by morphology immediately at treatment or 
microinjection and at various time points.  Survival was assessed by counting clearly 
identifiable neurons with intact phase-bright cell bodies, whereas dead neurons were 
atrophied.  Cell survival was expressed as a percentage of the original number of treated or 
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microinjected cells.  This method of assessing survival correlates well with other cell survival 
assays such as staining with calcein AM or trypan blue exclusion (Potts et al., 2003).  Data 
presented are mean ± s.e.m analyzed by Student’s t-test.  Experiments were done at least 
three times.  Boiled 500 U/ml IFN-γ, boiled 5 min at 99˚C, serves as a negative control.  All 
IFN-γ treatments are 500 U/ml unless otherwise stated. 
  
Quantitative RT-PCR: 
Total RNA was extracted from sympathetic neurons using Trizol Reagent (Invitrogen, 
Carlsbad, CA, USA) or RNeasy mini kit (Qiagen, Germantown, MD, USA) as per protocol.  
200-1000 ng RNA was converted to cDNA using previously described methods (Kole et al., 
2011).  Each 25 μl PCR reaction contained 25 ng cDNA, 400 nM of each primer, and 
PowerSYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK).  Primers were 
designed using Primer Express software (Applied Biosystems) or obtained from the 
literature (sequences in Table 2.1).  For each set of primers, post-amplification melting 
curves were performed to verify a single amplification product.  Amplification was 
conducted in an ABI7500 system (Applied Biosystems) and relative quantification was 
calculated using the 2-ΔΔCT method.  5-6 samples per group were run in triplicate with a 
negative control (no SuperScript II).  Significance was determined by a one-tailed Mann-
Whitney statistical test.  Results were duplicated in at least three independent experiments 
and target gene expression was normalized to 18S or GAPDH levels.   
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Table 2.1.  qRT-PCR primers (5’-3’) used in this study.  
Gene  Forward Reverse 
Ifi202b GCAGTGGCATCCTAGAGATCAA TTGGGCACTTCAATAATTTGGTT 
18S TTGACGGAAGGGCACCACCAG GCACCACCACCCACGGAATCG 
(Sato et al., 2013) 
Gapdh TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGA 
 
Microarray analysis: 
Total RNA was purified from sympathetic neurons treated with or without 500 U/ml 
IFN-γ for 24 hours using Trizol Reagent (Invitrogen) as per protocol.  RNA integrity was 
assessed on a 2100 Bioanalyzer using an RNA6000 nano chip (Agilent Technologies, Sugar 
Land, TX, USA) and concentration was quantified using a NanoDrop 1000 
spectrophotometer.  500 ng RNA per sample was labeled using the Low Input Quick Amp 
Labeling Kit (Agilent Technologies) per manufacturer instructions.  500 ng RNA from 
untreated P5 sympathetic cervical ganglia was amplified and labeled with Cy3 as a reference 
for each sample.  Overnight hybridization of two-color whole mouse genome 4x44K 
microarrays (Agilent Technologies) and scanning on an Agilent G2505C microarray scanner 
were performed at the UNC Genomics Core according to manufacturer recommendations.  
500 ng RNA from untreated P5 sympathetic neuron served as an internal reference for each 
slide.  Raw data was processed and analyzed by GeneSpring GX Version 11.0 (Agilent 
Technologies).  Genes with a corrected P value <0.05 following unpaired t-test and 
Benjamini and Hochberg false discovery rate procedure were considered differentially 
expressed. 
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Image acquisition and processing: 
Images were acquired by an ORCA-ER digital B/W CCD camera (Hamamatsu) 
mounted on a DMI6000 B inverted fluorescence microscope (Leica) using MetaMorph 
version 7.6 software (Molecular Devices).  Adobe Photoshop was used to adjust size and 
crop images to prepare the final figures.   
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2.4  Results 
IFN-γ suppresses neuronal apoptosis induced by NGF deprivation and pan-kinase 
inhibition 
IFN-α/β/γ induce apoptosis or increase sensitivity to apoptosis in many cell types 
(Dijkmans et al., 1990; Baerwald and Popko, 1998; Barber, 2000; Becher et al., 2000; 
Chawla-Sarkar et al., 2003; Clemens, 2003; Schroder et al., 2004; Pokrovskaja et al., 2005; 
Maher et al., 2007; Zhang et al., 2008; Das et al., 2009), however, there is evidence that IFN-
γ inhibits apoptosis in sympathetic neurons undergoing NGF deprivation (Chang et al., 
1990).  To determine whether interferons affect neuronal apoptosis, we exposed 
sympathetic neurons. to apoptotic stimuli with or without IFN-γ.  By 36 hours, 80% of 
sympathetic neurons died with NGF deprivation, however about 55% remained alive with 
addition of IFN-γ (Figure 2.1a).  This antiapoptotic effect of IFN-γ was not specific to NGF 
deprivation as IFN-γ addition also inhibited sympathetic neuronal apoptosis in response to 
staurosporine (STS) addition.  While fewer than 20% of sympathetic neurons alive at 72 hrs 
after STS addition, IFN-γ treatment promoted the survival of 60% of neurons at this 
timepoint (Figure 2.1b).  500 U/ml IFN-γ was observed to be the concentration yielding the 
highest, most consistent saving of sympathetic neurons (Supplemental Figure 2.1a).  
Remarkably, sympathetic neurons treated with NGF deprivation (or STS, images not shown) 
and IFN-γ resembled healthy control neurons, with intact neurites and smaller but phase-
bright cell bodies (Figure 2.1c).  While Kim et al. found that IFN-γ induces dendritic 
retraction and reduced neurite outgrowth in sympathetic neurons, we did not observe this 
in our model (Kim et al., 2002).  Type I IFN at high concentrations also protects neurons 
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from apoptosis with NGF deprivation or STS (data not shown) (Chang et al., 1990).  IFN-γ 
had no impact on apoptosis of sympathetic neurons treated with DNA damage or ER stress 
(Supplemental Figure 2.1b and c).  Together, these data indicate that IFN-γ protects 
sympathetic neurons from apoptosis with NGF deprivation or pan-kinase inhibition.  Chang 
et al. (Chang et al., 1990) previously reported reduced apoptosis in IFN-γ-treated 
sympathetic neurons with NGF deprivation, yet how IFN-γ alters the neuronal apoptotic 
pathway is unknown.   
 
IFN-γ blocks apoptosis at the point of cytochrome c release in NGF-deprived neurons 
To determine the precise effects of IFN-γ function on neuronal apoptosis, we 
investigated the result of IFN-γ treatment on specific steps of the apoptotic pathway 
induced by NGF deprivation.  NGF withdrawal leads to the phosphorylation and activation 
of transcription factor c-Jun, which upregulates BH3-only proteins, resulting in 
mitochondrial cytochrome c release, caspase activation, and cell death (Figure 2.2a) (Eilers, 
Whitfield et al. 1998; Whitfield, Neame et al. 2001).  We first examined phospho-c-Jun, 
which is upregulated and translocates to the nucleus upon activation.  Robust staining of 
nuclear phospho-c-Jun was similar in sympathetic neurons treated with or without IFN-γ at 
12 hours of NGF deprivation, indicating that IFN-γ did not affect c-Jun phosphorylation 
(Figure 2.2b).     
Next, we tested the effect of IFN-γ on cytochrome c release from the mitochondria.  
Following NGF deprivation, cytochrome c staining is faint, indicating release into the cytosol 
(Deshmukh and Johnson, 1998).  Neurons treated with IFN-γ, however, maintained 
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cytochrome c staining in the mitochondria, demonstrating IFN-γ blocks mitochondrial 
permeabilization in response to NGF deprivation (Figure 2.2c).  IFN-γ also blocked caspase-3 
activation downstream of cytochrome c release in response to NGF deprivation (Figure 
2.2d).  Consistent with these findings, Western blot analysis showed no change in phospho-
c-Jun or BH3-only proteins, Bim and Puma, but a decrease in active caspase-3 with IFN-γ 
addition with NGF deprivation (Figure 2.2e).  Levels of additional apoptosis-related proteins 
remained unchanged (Supplemental Figure 2.1).  Thus, these findings demonstrate that IFN-
γ inhibits apoptosis in neurons downstream of BH3 protein induction and upstream of 
cytochrome c release. 
 
IFN-γ does not alter apoptosis downstream of cytochrome c release 
Our data reveal a distinct suppression of active caspase-3 with IFN-γ treatment in 
NGF-deprived neurons.  Previous research shows that interferons can regulate expression of 
caspases and caspase inhibitors to modulate apoptosis downstream of mitochondrial 
permeabilization (Chawla-Sarkar et al., 2003; Clemens, 2003; Pokrovskaja et al., 2005).  To 
investigate whether IFN-γ also acts downstream of cytochrome c release, we microinjected 
cytochrome c into XIAP-/- sympathetic neurons with or without IFN-γ 24 hr pretreatment.  
Cytochrome c induced similar rates of cell death in treated neurons, demonstrating that 
IFN-γ does not suppress the apoptotic pathway downstream of cytochrome c release 
(Figure 2.3). 
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IFN-γ modulates gene expression in sympathetic neurons 
Interferons stimulate expression of pro-apoptotic genes, including Fas, TRAIL, XAF-1, 
and caspases, in a variety of cell types, which induces apoptosis in these cells either with or 
without additional stressors (Dijkmans et al., 1990; Baerwald and Popko, 1998; Barber, 
2000; Becher et al., 2000; Chawla-Sarkar et al., 2003; Clemens, 2003; Schroder et al., 2004; 
Pokrovskaja et al., 2005; Maher et al., 2007; Zhang et al., 2008; Das et al., 2009).  To first 
determine whether IFN-γ modulates gene expression in sympathetic neurons as it does in 
other cell types, we conducted quantitative RT-PCR on sympathetic neurons with or without 
IFN-γ.  Levels of ifi202b, an interferon-responsive gene in the HIN-200 family, increased 30-
fold with 24 hours of IFN-γ treatment (Figure 2.4).  This finding reveals that IFN-γ modulates 
gene expression in sympathetic neurons, indicating it is possible IFN-γ exerts its anti-
apoptotic effects in neurons by regulating gene expression.   
To evaluate whether IFN-γ stimulates the expression of genes regulating apoptosis in 
neurons as it does in other cell types, we conducted a microarray experiment comparing 
gene expression of sympathetic neurons with or without 500 U/ml IFN-γ.  24 hours of IFN-γ 
exposure in neurons significantly upregulated many interferon-inducible genes including 
Stat1 and the HIN-200 gene family, while downregulating only five genes (Table 2.2).  
Microarray data have been deposited in Gene Expression Omnibus under the accession 
number GSE48683.  Surprisingly, although IFN-γ protects sympathetic neurons from 
apoptosis, pro-apoptotic gene Trail (Tnfsf10) is upregulated yet no anti-apoptotic genes 
were significantly altered by IFN-γ (Table 2.2).  Among the pro-death genes that are 
upregulated by IFN-γ in other cell types, very few of these genes were induced by IFN-γ in 
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sympathetic neurons (Table 2.3).  However,  Irf1, Irf8 (interferon-regulatory factor 1 and 8) 
and PKR (protein kinase, interferon-inducible double stranded RNA dependent), genes that 
promote cell death through the extrinsic pathway in other cell types (Barber, 2000; Chawla-
Sarkar et al., 2003; Clemens, 2003; Schroder et al., 2004; Pokrovskaja et al., 2005) were 
strongly upregulated by IFN-γ in these neurons (Table 2.3).  Interestingly, Ifi202b has been 
shown to either promote or inhibit apoptosis, depending on the cell type, by binding and 
inhibiting transcription factors including c-Jun, c-Fos, c-Myc, NF-κB, E2F2, and p53 (Min et 
al., 1996; Asefa et al., 2004; Choubey and Panchanathan, 2008; Mondini et al., 2010).  
Although we found ifi202b to be strongly upregulated by IFN-γ in sympathetic neurons 
(Figure 2.4 and Table 2.3), microinjection of ifi202b plasmid or sh-ifi202b into neurons did 
not affect apoptosis with NGF deprivation (data not shown). 
Together, these data demonstrate that, while IFN-γ prompts apoptosis in other cell 
types, IFN-γ exerts an anti-apoptotic effect on sympathetic neurons by blocking apoptosis at 
the point of cytochrome c release. 
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2.5  Discussion 
In this study, we examined the effects of IFN-γ on sympathetic neuron survival.  We 
found that, while sympathetic neuron survival was not affected by IFN-γ alone, IFN-γ 
inhibited neuronal apoptosis with NGF-deprivation or pan-kinase inhibition, but not with 
DNA damage or ER stress.  IFN-γ treatment of NGF-deprived sympathetic neurons did not 
alter c-Jun phosphorylation or induction of BH-3 only genes, but decreased mitochondrial 
cytochrome c release and subsequent caspase 3 activation.  Although some studies report 
upregulation of caspases and XAF-1 by interferons (Chawla-Sarkar et al., 2003; Clemens, 
2003; Maher et al., 2007) cytochrome c injection experiments showed that IFN-γ did not 
affect neuronal apoptosis downstream of the mitochondria.  Finally, we report that IFN-γ 
modulated gene expression in sympathetic neurons, including the upregulation of 
apoptosis-related genes, including ifi202b.  While ifi202b is implicated in apoptosis 
inhibition in other cell types (Choubey and Panchanathan, 2008), ifi202b knockdown and 
overexpression did not alter neuronal apoptosis.  These results demonstrate that despite 
IFN-γ inducing expression of several pro-apoptotic genes in sympathetic neurons, IFN-γ 
suppresses apoptosis at the point of mitochondrial permeabilization during NGF 
deprivation.   
The ability of IFN-γ to suppress apoptosis in sympathetic neurons is quite intriguing.  
IFN-γ has been reported to activate p38 and JNK MAPK pathways (Xia et al., 1995; Bruckner 
et al., 2001; Kalvakolanu and Roy, 2005; Maher et al., 2007; Hervas-Stubbs et al., 2011), as 
well as suppress NF-κB activity (Hervas-Stubbs et al., 2011), either of which induce 
apoptosis in sympathetic neurons (Maggirwar et al., 1998; Bruckner et al., 2001).  Thus, 
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interferon’s pro-survival effect in sympathetic neurons suggests the inability of IFN-γ to 
activate JNK or suppress NF-κB in these neurons, which would promote apoptosis.  
Similarly, inhibition of transcription or translation inhibits apoptosis in sympathetic neurons 
(Martin et al., 1988; Xia et al., 1995).  Although interferon inhibits protein synthesis through 
activation of EIF2α to limit viral replication (Xia et al., 1995; Chawla-Sarkar et al., 2003; 
Schroder et al., 2004; Pokrovskaja et al., 2005), induction of BH3-only protein was not 
suppressed in IFN-γ-treated NGF-deprived neurons (Figure 22).  Interestingly, BH3-only 
protein induction is inhibited by miR-29 (Kole et al., 2011), which is upregulated by IFN-γ in 
melanoma cells (Schmitt et al., 2012).  In this study, we found no suppression of BH3-only 
induction in interferon-treated sympathetic neurons with NGF deprivation.   
While neurons upregulated several pro-apoptotic genes (Trail, Irf1, Irf8, PKR) in 
response to interferon, it was not sufficient to cause apoptosis in NGF-maintained or 
deprived sympathetic neurons.  Previous research shows that sympathetic neuron survival 
is resistant to TNF-α (Marz et al., 1996) and there is no literature on the expression or ability 
of death receptor ligands to activate the extrinsic apoptotic pathway in sympathetic 
neurons.  Therefore, it is possible that these neurons are insensitive to this gene 
upregulation (due to lack of death receptor expression), pro-apoptotic signals were 
insufficient to promote apoptosis, or a pro-survival mechanism(s) such as Mig (monokine 
induced by interferon-gamma) (Uwabe et al., 2005) overrode the pro-death signal. 
Cytochrome c release is the point of divergence for IFN-treated neurons undergoing 
NGF deprivation, suggesting Bax activation as the likely molecule altering mitochondrial 
permeabilization.  Our data at the protein level excludes main modulators of Bax activation, 
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Bcl-XL as well as the BH3-only proteins, however Bax-activating candidates Ku70 (Cohen et 
al., 2004) and phosphorylated Bim have not been excluded (Lei and Davis, 2003; 
Pokrovskaja et al., 2005).  Inhibition of mitochondrial permeabilization by IFN-γ prevents 
damage to this important organelle, allowing maintenance of neuronal metabolism.  
Although some studies report upregulation of caspases and XIAP inhibitor, XAF-1, by 
interferons (Chawla-Sarkar et al., 2003; Clemens, 2003; Maher et al., 2007), cytochrome c 
injection experiments showed that IFN-γ did not affect neuronal apoptosis downstream of 
the mitochondria.   
Bernabei et al. proposed that cells with higher levels of IFN-γ receptor (IFN-γR2) 
undergo rapid Stat1 activation of apoptosis in response to IFN-γ, while a slower Stat1 
activation with lower levels of IFN-γ receptor does not induce apoptosis (Bernabei et al., 
2001; Bernabei et al., 2001; Boselli et al., 2010).  However, sympathetic neurons express 
IFN-γ receptors at a higher level than cortical neurons, which undergo apoptosis in response 
to IFN-γ (Rottenberg and Kristensson, 2002; Dedoni et al., 2012).  Thus, expression of the 
IFN-γ receptor does not appear to be the determining factor of apoptosis in neurons. 
An infection or injury stimulates interferon production and recruitment of 
macrophages, natural killer (NK) cells, and T lymphocytes (Chawla-Sarkar et al., 2003; 
Schroder et al., 2004).  IFN-γ activates macrophages to release nitric oxide radicals, which 
can contribute to neuronal death (Rottenberg and Kristensson, 2002).  Sympathetic neurons 
co-cultured with active, but not resting, macrophages triggered neurite loss and neuronal 
death (Arantes et al., 2000; Almeida-Leite et al., 2007).  Similarly, activated T cells or NK 
cells following IFN-γ exposure can mediate neurite and DRG and hippocampal neuron 
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elimination (Rottenberg and Kristensson, 2002; Yong et al., 2007).  In vivo, CD8+ T cells 
entering Borna disease virus (BDV) infected brain did not cause hippocampal neuron death 
unless the mice lacked IFN-γ (Richter et al., 2009).  Therefore, IFN-γ’s ability to promote 
neuronal survival may counteract the cytotoxic signals from immune cells in the neurons’ 
milieu as well as protecting neurons from death due to viral infection (Burdeinick-Kerr et al., 
2009). 
Overall, these findings demonstrate that sympathetic neurons, unlike most cell 
types, respond to interferon by suppressing the apoptotic pathway at the point of 
mitochondrial permeabilization.  Despite upregulation of several proapoptotic genes, 
neurons treated with IFN-γ display a remarkable ability to suppress cell death with NGF 
deprivation or pan-kinase inhibition.  The ability  of  IFN-γ to promote sympathetic neuronal 
survival while inducing pathways that kill pathogens is likely a physiologically important 
mechanism which could ensure the long-term survival of these neurons during critical 
situations of pathogenic infection.  
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2.6  Figures and Legends 
 
Figure 2.1.  IFN-γ protects neurons from apoptosis in response to nerve growth factor 
deprivation or pan-kinase inhibition.   
 
Neurons were treated with (A) nerve growth factor (NGF) deprivation or (B) staurosporine 
(pan-kinase inhibition; STS) with or without 500 U/ml IFN-γ and survival was assessed by 
morphology at 36 hours or 72 hours, respectively.  Boiled 500 U/ml IFN-γ, boiled 5 min at 
99˚C, served as a negative control.  (C) Phase images were taken of neurons after 40 hours 
of NGF deprivation.  Data represent mean +/- s.e.m. analyzed by Student’s t-test.  
Experiments were done at least three times.  * P<0.05; **P<0.01; *** P<0.001. 
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Figure 2.1 
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Figure 2.2.  IFN-γ inhibits apoptosis at the point of cytochrome c release.   
 
(A)  Schematic representation of the apoptosis pathway induced after NGF deprivation.  (B)  
Neurons were untreated or deprived of NGF with or without IFN-γ and fixed for phospho-c-
Jun immunofluorescence at 12 hours.  Percentage of cells with phospho-c-Jun nuclear 
staining and representative images of phospho-c-Jun staining in neurons.  Data is mean ± 
std. dev.  (C)  Neurons were untreated or deprived of NGF with or without IFN-γ, in the 
presence of caspase inhibitor, QVD, and fixed for cytochrome c immunofluorescence at 48 
hours.  Data is mean percentage of cells with mitochondrial cytochrome c staining ± s.e.m. 
analyzed by the Student’s t-test.  *P= 0.0279.  Images are representative of neurons with 
cytochrome c staining.  (D)  Neurons were untreated or deprived of NGF with or without 
IFN-γ and fixed for cleaved-caspase-3 (c-Casp3) immunofluorescence at 24 hours.  Data is 
mean percentage of cells with c-Casp3 staining ± std. dev.  Images are representative of 
neurons with c-Casp3 staining.  (E)  Neurons were untreated, deprived of NGF, or deprived 
of NGF with 200 U/ml or 500 U/ml IFN-γ.  Cell lysates were collected at 24 hours and 
examined by western blotting analysis.  500 U/ml IFN-γ reduces cleaved caspase-3 but does 
not alter levels of phospho-c-Jun or induction of BH3-only apoptotic proteins.   
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Figure 2.2
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Figure 2.2 continued 
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Figure 2.3.  IFN-γ does not alter the apoptotic pathway downstream of cytochrome c 
release.   
 
Cell death with microinjection of cytochrome c was equivalent with and without IFN-γ 
addition.  XIAP-/- neurons pretreated with or without IFN-γ for 24 hours were microinjected 
with cytochrome c and survival was assessed by morphology.  Data are mean ± s.e.m. of 
four independent experiments with at least 40 cells injected per experiment. 
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Figure 2.3 
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Figure 2.4.  IFN-γ regulates gene expression in sympathetic neurons.   
 
Quantitative RT-PCR analysis demonstrating neurons exhibit upregulated expression of 
interferon-inducible ifi202b mRNA with 24 hours 500 U/ml IFN-γ treatment.  Ifi202b 
expression is normalized to 18S levels.  Data are mean of at least five samples per group ± 
s.e.m. analyzed by the Mann-Whitney test.  **P=0.0043. 
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Figure 2.4 
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Table 2.2.  IFN-γ modulates gene expression in sympathetic neurons.   
 
Summary of genes differentially expressed with 24 hours 500 U/ml IFN-γ in sympathetic 
neurons (P<0.05 following unpaired t-test and Benjamini and Hochberg false discovery rate 
procedure). 
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Table 2.2    
Symbol Gene Name Fold change 
Up-regulated   
Gbp3 guanylate nucleotide binding protein 3 142 
Gvin1 GTPase, very large interferon inducible 1 111 
Ifi44 interferon-induced protein 44 101 
Rtp4 receptor transporter protein 4 65 
Batf2 basic leucine zipper transcription factor, ATF-like 2 59 
Irgb10 interferon-gamma-inducible p47 GTPase 51 
Igtp interferon gamma induced GTPase 37 
Tnfsf10 (Trail) tumor necrosis factor (ligand) superfamily, member 10 34 
Parp14 poly (ADP-ribose) polymerase family, member 14 23 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 23 
Gbp6 guanylate binding protein 6 22 
Stat1 signal transducer and activator of transcription 1 18 
Mx2 myxovirus (influenza virus) resistance 2 18 
RP23-14F5.8 similar to T-cell specific GTPase 18 
Ifi204 interferon activated gene 204 17 
Irgm immunity-related GTPase family, M 17 
Iigp2 interferon inducible GTPase 2 16 
Isg15 ISG15 ubiquitin-like modifier 15 
Gbp2 guanylate nucleotide binding protein 2 15 
Ifih1 interferon induced with helicase C domain 1 14 
Tap1 transporter 1, ATP-binding cassette (MDR/TAP) 14 
Tgtp T-cell specific GTPase 13 
Ifi203 interferon activated gene 203 13 
Fbxo39 F-box protein 39 12 
Irf8 interferon regulatory factor 8 12 
Bst1 bone marrow stromal cell antigen 1 12 
Rsad2 radical S-adenosyl methionine domain containing 2 12 
Parp9 poly (ADP-ribose) polymerase family, member 9 11 
Ifi203 interferon activated gene 203 11 
Oasl2 2'-5' oligoadenylate synthetase-like 2 9.9 
RP23-14F5.7 hypothetical gene Rp23-14f5.7 9.8 
Irf1 interferon regulatory factor 1 9.7 
Oas1g 2'-5' oligoadenylate synthetase 1G 9.6 
H2-T22 histocompatibility 2, T region locus 22 9.5 
Psmb9 proteosome (prosome, macropain) subunit, beta type 9 9.4 
Bst2 bone marrow stromal cell antigen 2 9.0 
Il18bp interleukin 18 binding protein 8.9 
Gls Glutaminase 8.1 
Socs1 suppressor of cytokine signaling 1 7.8 
Herc5 hect domain and RLD 5 7.6 
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Psmb8 proteosome (prosome, macropain) subunit, beta type 8 6.7 
Cd274 CD274 antigen 6.6 
Myh7 myosin, heavy polypeptide 7, cardiac muscle, beta 6.2 
Tap2 transporter 2, ATP-binding cassette (MDR/TAP) 6.2 
Cd52 CD52 antigen 5.8 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 5.7 
Tex14 testis expressed gene 14 5.7 
Abhd8 abhydrolase domain containing 8 5.5 
Samhd1 SAM domain and HD domain, 1 5.4 
Parp12 poly (ADP-ribose) polymerase family, member 12 5.4 
Psmb10 proteasome (prosome, macropain) subunit, beta type 10 5.0 
B2m beta-2 microglobulin 4.8 
Arts1 type 1 TNF receptor shedding aminopeptidase regulator 4.6 
Pnpla5 patatin-like phospholipase domain containing 5 3.9 
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 3.9 
Ly75 lymphocyte antigen 75 3.8 
Plec1 plectin 1 3.7 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 3.7 
Slamf8 SLAM family member 8 3.6 
Psme2 proteasome (prosome, macropain) 28 subunit, beta 3.4 
Pla1a phospholipase A1 member A 3.3 
Nmi N-myc (and STAT) interactor 3.2 
Tapbp TAP binding protein 3.1 
Tnfsf13b tumor necrosis factor (ligand) superfamily, member 13b 3.1 
Isgf3g IFN dependent positive acting transcription factor 3 gamma 3.1 
Ifi35 interferon-induced protein 35 3.0 
Lap3 leucine aminopeptidase 3 2.9 
Megf6 multiple EGF-like-domains 6 2.6 
Ube2l6 ubiquitin-conjugating enzyme E2L 6 2.5 
Pbef1 pre-B-cell colony-enhancing factor 1 2.5 
Zfp313 zinc finger protein 313 2.4 
H2-Oa histocompatibility 2, O region alpha locus 2.1 
Psme1 proteasome (prosome, macropain) 28 subunit, alpha 2.0 
Spo11 sporulation protein, meiosis-specific, SPO11 homolog  2.0 
Col23a1 procollagen, type XXIII, alpha 1 1.9 
Rbm4 RNA binding motif protein 4 1.2 
Down-regulated   
Olfr912 olfactory receptor 912 -2.3 
Chrnb2 cholinergic receptor, nicotinic, beta polypeptide 2 -1.3 
Tmem110 transmembrane protein 110 -1.2 
Tktl2 transketolase-like 2 -1.2 
Polr2e polymerase (RNA) II (DNA directed) polypeptide E -1.1 
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Table 2.3.  Sympathetic neurons upregulate few pro-apoptotic genes in response to IFN-γ.   
 
Expression of genes reported to be regulated by interferon in other cell types (Koul et al., 
1998; Choi et al., 1999; Barber, 2000; Nishikawa et al., 2001; Chawla-Sarkar et al., 2003; 
Clemens, 2003; Schroder et al., 2004; Pokrovskaja et al., 2005; Maher et al., 2007) were 
evaluated by gene array in sympathetic neurons treated with 24 hours 500 U/ml IFN-γ.  
Indicated P value is corrected P value following unpaired t-test and Benjamini and Hochberg 
false discovery rate procedure (ns= non-specific). 
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Table 2.3 
Symbol Gene Name Fold change P value 
Pro-apoptotic    
Fas Fas (TNF receptor superfamily member) 2.1 ns 
FasL Fas ligand (TNF superfamily, member 6) -1.0 ns 
Trail   tumor necrosis factor (ligand) superfamily 10 34.1 0.0178 
Trail receptor TNF receptor superfamily, member 10b -1.0 ns 
TNF  tumor necrosis factor 2.5 ns 
TNFα receptor TNF receptor superfamily, member 1a 1.4 ns 
Fadd Fas (TNFRSF6)-associated via death domain -1.0 ns 
Daxx Fas death domain-associated protein 1.2 ns 
Bak1 BCL2-antagonist/killer 1 1.2 ns 
Bax Bcl2-associated X protein 1.1 ns 
Casp1 caspase 1 5.3 ns 
Casp3 caspase 3 1.1 ns 
Casp4 caspase 4 3.1 ns 
Casp7 caspase 7 3.0 ns 
Casp8 caspase 8 1.4 ns 
Casp9 caspase 9 -1.1 ns 
RnaseL ribonuclease L -1.0 ns 
Irf1 interferon regulatory factor 1 9.7 0.0177 
Irf2 interferon regulatory factor 2 1.1 ns 
Irf3 interferon regulatory factor 3 1.0 ns 
Irf4 interferon regulatory factor 4 -1.6 ns 
Irf5 interferon regulatory factor 5 1.8 ns 
Irf6 interferon regulatory factor 6 -1.5 ns 
Irf7 interferon regulatory factor 7 8.0 ns 
Irf8 interferon regulatory factor 8 12.3 0.028 
PKR eukaryotic translation initiation factor 2-α kinase 2 3.5 0.054 
OAS1 2'-5' oligoadenylate synthetase 1 3.1 ns 
Oas3 2'-5' oligoadenylate synthetase 3 5.4 ns 
Pml promyelocytic leukemia 1.4 ns 
Dap death-associated protein -1.2 ns 
Dap3 death associated protein 3 1.0 ns 
Dapk1 death associated protein kinase 1 -1.1 ns 
Dapk2 death-associated kinase 2 1.8 ns 
Dapk3 death-associated kinase 3 -1.1 ns 
Hif1a hypoxia inducible factor 1, alpha subunit 1.2 ns 
Plscr1 phospholipid scramblase 1 1.5 ns 
Plscr2 phospholipid scramblase 2 2.1 ns 
Plscr3 phospholipid scramblase 3 1.1 ns 
Plscr4 phospholipid scramblase 4 1.1 ns 
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p21 cyclin-dependent kinase inhibitor 1A (P21) -1.5 ns 
Ctsd cathepsin D -1.2 ns 
Anti-apoptotic    
Bcl2 B-cell leukemia/lymphoma 2 -1.4 ns 
Bcl-XL  Bcl2-like 1 (Bcl2l1) -1.1 ns 
XIAP baculoviral IAP repeat-containing 4 (Birc4) -1.0 ns 
c-FLIP CASP8 and FADD-like apoptosis regulator (Cflar) 1.2 ns 
Survivin baculoviral IAP repeat-containing 5 (Birc5) 2.5 ns 
Pro- or anti-apoptotic   
Mcl1 myeloid cell leukemia sequence 1 1.1 ns 
ifi202 interferon activated gene 202B 21.7 0.112 
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Supplemental Figure 2.1.  Varying concentrations of IFN-γ protect sympathetic neurons 
from apoptosis with NGF deprivation but IFN-γ does not protect neurons from DNA 
damage or ER stress.   
 
(A)  Neurons were treated with NGF deprivation and with varying concentrations of IFN-γ 
and survival was assessed by morphology at 36 hours.  (B) Neurons were subjected to DNA 
damage with etoposide or (C) ER stress with tunicamycin with or without 500 U/ml IFN-γ 
and survival was assessed by morphology at 72 hours or 48 hours, respectively.  Boiled 500 
U/ml IFN-γ, boiled 5 min at 99˚C, served as a negative control.  Experiments were done at 
least three times. 
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Supplemental Figure 2.1 
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Supplemental Figure 2.2.  IFN-γ doesn’t alter pro-caspase-3 or other apoptotic proteins in 
neurons.   
 
Neurons were untreated, deprived of NGF, or deprived of NGF with 200 U/ml or 500 U/ml 
IFN-γ.  Cell lysates were collected at 24 hours and examined by western blotting analysis.  
Levels of indicated pro- and anti- apoptotic proteins are unchanged by IFN-γ. 
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Supplemental Figure 2.2 
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CHAPTER III:  ASC DEFICIENCY SUPPRESSES PROLIFERATION AND PREVENTS 
MEDULLOBLASTOMA INCIDENCE 
 
3.1  Overview 
Apoptosis-associated speck-like protein containing a caspase recruitment domain 
(ASC) is silenced by promoter methylation in many types of tumors, yet ASC’s role in most 
cancers remains unknown.  Here, we show that ASC is highly expressed in a model of 
medulloblastoma, the most common malignant pediatric brain cancer.  Importantly, while 
ASC deficiency did not affect normal cerebellar development, ASC knock-out mice in the 
Smoothened (ND2:SmoA1) transgenic model of medulloblastoma exhibited a profound 
reduction in medulloblastoma incidence and delayed tumor onset.  Additionally, ASC 
deficiency increased age at tumor onset in a second model of medulloblastoma, GFAP-
Cre:SmoM2 mice.  Premalignant lesions in cerebella of ASC-/-;ND2:SmoA1 mice displayed a 
striking decrease in number of ectopic progenitors.  While proliferation rates decreased 
with ASC deletion, apoptosis and differentiation markers remained unchanged.  
Interestingly, ASC deficiency disrupted expression of genes in the TGF-β pathway and 
increased the level of nuclear Smad3 in this medulloblastoma model.  Together, these 
results demonstrate an unexpected requirement for ASC in Sonic hedgehog-driven 
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medulloblastoma tumorigenesis, thus identifying ASC as a promising novel target for anti-
tumor therapy.   
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3.2  Introduction 
Medulloblastoma, a tumor of cerebellar progenitors, is the most common malignant 
brain cancer in children (Hatten and Roussel, 2011).  During normal development, 
proliferation of progenitors in the cerebellum extends into the early postnatal period, as 
cerebellar granule neuron progenitors (CGNPs) undergo rapid division in the external 
granule layer (EGL), then differentiate and migrate to the internal granule layer (IGL) 
(Hatten and Heintz, 1995).  CGNPs proliferate in response to endogenous Sonic hedgehog 
(Shh; mouse), and mutations that activate SHH (human) signaling cause predisposition to 
medulloblastoma in humans with Gorlin Syndrome, and in genetically engineered mouse 
models (Polkinghorn and Tarbell, 2007; Hatten and Roussel, 2011).  These models, which 
operate through either Patched deletion or insertion of constitutively active alleles of 
Smoothened (Smo), consistently implicate CGNPs as the cells of origin for Shh-driven 
medulloblastoma (Hallahan, Pritchard et al. 2004; Yang, Ellis et al. 2008).  Importantly, while 
advances in treatment have increased the survival of patients with medulloblastoma, 
mortality remains significantly high and debilitating cognitive and endocrine side effects 
result from current treatment regimens (Polkinghorn and Tarbell, 2007).  Thus, advancing 
the understanding of the genetic components of medulloblastoma tumorigenesis is needed 
to develop improved targeted therapies. 
ASC (apoptosis-associated speck-like protein containing a caspase recruitment 
domain; also known as TMS-1, target of methylation-induced silencing-1) is expressed in 
many human tissues, however, is silenced by promoter hypermethylation in many tumor 
types, including glioblastoma (Stone et al., 2004), neuroblastoma (Alaminos et al., 2004), 
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breast cancer (Conway et al., 2000), melanoma (Guan et al., 2003), and lung cancer 
(Machida et al., 2006).  Ectopic ASC expression sensitizes pancreatic, breast, and colon 
cancer cells to apoptosis (Conway et al., 2000; Ohtsuka et al., 2004; Ohtsuka et al., 2006; 
Parsons and Vertino, 2006; Ramachandran et al., 2010; Hong et al., 2013), while knocking 
down endogenous ASC inhibits cell death of osteosarcoma cells (Ohtsuka et al., 2004), colon 
cells (Hong et al., 2013), and breast epithelial cells (Parsons et al., 2009).  Additionally, ASC 
is the adaptor protein of the inflammasome, a cytosolic complex that senses pathogen-
associated molecules and subsequently responds by activating pro-inflammatory 
substrates, pro-interleukin-1β (pro-IL-1β) and pro-IL-18, which recruit and activate immune 
cells (Fernandes-Alnemri et al., 2009; Franchi et al., 2009; Davis et al., 2011).  Consistent 
with the expectation that ASC inactivation promotes tumorigenesis, ASC-deficiency has 
been shown to enhance polyp formation in a colitis-associated colon cancer mouse model 
(Allen et al., 2010; Zaki et al., 2010).  Together, these studies point to ASC as a functional 
tumor suppressor. 
In this study, we examined the role of ASC in medulloblastoma using the ND2:SmoA1 
transgenic mouse model.  Our results reveal the unexpected finding that ASC promotes 
tumorigenesis in medulloblastoma.  ASC was highly expressed in these tumors and the 
genetic deletion of ASC markedly reduced proliferation, hyperplasia, and mortality.  These 
findings identify a novel role for ASC in promoting tumorigenesis in medulloblastoma. 
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3.3  Results and Discussion 
 
ASC is highly expressed in medulloblastomas 
To investigate the role of ASC in cerebellar development and medulloblastoma, we 
evaluated ASC expression during mouse cerebellum development.  ASC protein levels were 
high in postnatal-day 7 (P7) cerebellum, which corresponds to the peak period of CGNP cell 
proliferation, and decreased with cerebellar maturation (Figure 3.1a).  ASC is reported to 
enhance apoptosis upon expression and is often silenced via methylation in a variety of 
cancers (Conway et al., 2000; Ohtsuka et al., 2004; Ohtsuka et al., 2006; Parsons and 
Vertino, 2006; Allen et al., 2010; Ramachandran et al., 2010).  To determine whether ASC 
was also silenced in cancer of cerebellar origin, we examined ASC expression in 
medulloblastoma.   We used the ND2:SmoA1 (SmoA1) mouse model of medulloblastoma 
which expresses the activated allele of Smo in CGNPs, resulting in CGNP hyperproliferation 
and tumor growth as a consequence of the constitutive activation of the Sonic hedgehog 
pathway (Hallahan et al., 2004).  In contrast to the reports in other cancer types, we 
unexpectedly detected high levels of ASC in medulloblastoma (Figure 3.1a).  Also, ASC 
mRNA levels closely matched protein levels throughout development and in the tumor 
(Figure 3.1b).  These data reveal the surprising observation that ASC is not subjected to 
silencing but is induced in a mouse model of medulloblastoma. 
In human medulloblastoma, publicly available gene expression profiling data in the 
Oncomine database reveals ASC to be expressed in human medulloblastomas, with 
increased expression in desmoplastic versus classic tumors (Figure 3.1c) (Kool et al., 2008; 
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Fattet et al., 2009).  Since SHH-associated medulloblastomas are generally characterized by 
a desmoplastic histology (Thompson et al., 2006; Cho et al., 2011; Fellay et al., 2011), this 
data suggests that ASC expression is more upregulated in medulloblastomas with SHH 
pathway disruption than other subtypes.  Thus, in SHH-driven medulloblastomas ASC is 
upregulated in both human and mouse tumors.   
 
ASC deficiency does not affect normal cerebellum development 
To investigate whether ASC expression is important in medulloblastoma 
tumorigenesis, we first evaluated whether ASC deficiency affected normal cerebellar 
development.  Cerebellar development occurs postnatally with rapid CGNP proliferation in 
the EGL peaking at P7.  As CGNPs terminally differentiate into cerebellar granule neurons 
(CGNs), they migrate to the IGL to form the mature cerebellum by P20 (Hatten and Heintz, 
1995).  We therefore compared cerebellar architecture of ASC+/+ and ASC-/- mice during this 
key developmental period.  H&E staining revealed no differences in gross morphology 
between wild-type and ASC-deficient cerebella throughout development (Figure 3.1d).   To 
specifically examine whether proliferation was altered by ASC deficiency, we compared 
expression of proliferation markers cyclin D2 and phospho-histone H3 (pH3) in ASC+/+ and 
ASC-/- P7 cerebellum.  No differences in cyclin D2 levels and pH3 staining were observed 
between wild-type and ASC-deficient cerebella (Figures 3.1e and f). 
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ASC deficiency suppresses SmoA1- and SmoM2-induced medulloblastoma 
Next, to determine whether ASC deficiency affects medulloblastoma, we generated 
ASC+/+, ASC+/-, and ASC-/- SmoA1 mice and compared the time of tumor emergence in each 
group.  In this Smo transgenic medulloblastoma model, signs of tumors typically emerge at 
3-8 months and precede death from the disease by only a few days; thus, once signs 
emerge, mice are in a moribund state (Hallahan et al., 2004).  Surprisingly, ASC deficiency 
conferred a striking reduction in tumor incidence and a delay in tumor onset in the SmoA1 
transgenic mice (Figure 3.2a).  Overall tumor incidence by P300 was significantly reduced in 
mice lacking ASC: while 12 of 15 ASC+/+;SmoA1 mice exhibited tumors, only 5 of 18 ASC-/-
;SmoA1 mice developed medulloblastoma (Figure 3.2b).  Additionally, ASC deficiency 
markedly delayed latency to tumor formation in ASC-/-;SmoA1 mice compared to 
ASC+/+;SmoA1 and ASC+/-;SmoA1  mice (Figure 3.2a).  ASC heterozygous SmoA1 mice also 
exhibited a delayed rate of tumorigenesis when compared to wild-type mice (Figure 3.2a).  
These results demonstrate a profound suppression of medulloblastoma tumorigenesis with 
ASC deletion.   
To test whether ASC deficiency affects tumorigenesis in another model of 
medulloblastoma, we utilized the SmoM2 model.  SmoM2 is a constitutively active Shh-
driving Smo mutation discovered to aggressively induce medulloblastoma in mice by P20 
(Xie et al., 1998; Jeong et al., 2004; Mao et al., 2006).  We generated ASC+/+, ASC+/-, and  
ASC-/- GFAP-Cre:SmoM2 (SmoM2) mice and evaluated time to tumor emergence and 
moribund status.  ASC deficiency markedly reduced tumorigenesis in the SmoM2 model, 
with loss of one or two ASC alleles extending survival (Figure 3.2c).  While all mice 
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developed medulloblastoma in this model, the average age at which mice became 
moribund was delayed in ASC heterozygous and knock-out mice (Figure 3.2d).  Thus, ASC 
deficiency profoundly reduced tumorigenesis and extended survival in two mouse models 
of medulloblastoma. 
In addition to other functions, ASC acts as the adaptor protein for the 
inflammasome, a complex that, when triggered by intracellular signals, cleaves 
proinflammatory substrate pro-IL-1β into its mature form (Fernandes-Alnemri et al., 2009; 
Franchi et al., 2009; Davis et al., 2011).  IL-1β has been reported to have several functions 
promoting cancer, although it has not been studied in medulloblastoma (Apte et al., 2006).  
To determine whether ASC requires IL-1β for medulloblastoma development, we evaluated 
tumorigenesis in IL-1β deficient mice in the SmoA1 model.  IL-1β deficiency did not affect 
medulloblastoma onset or incidence (Figures 3.2e and f). 
To determine the point at which ASC deficiency blocks tumorigenesis in 
medulloblastoma, we compared wild-type and ASC-deficient SmoA1 cerebella at multiple 
time points during tumor development.  In this tumor model, ectopic CGNP proliferation 
can be detected by P20 and progresses into tumor in adulthood.  To determine whether 
ASC deficiency affects CGNP hyperproliferation during the pre-tumor stages (P20, P60), 
histological H&E stained sections of ASC+/+ and ASC-/- SmoA1 cerebella were compared.   
ASC-/-;SmoA1 cerebella exhibited equivalent ectopic CGNP proliferation and EGL 
architecture as seen in ASC+/+;SmoA1 mice at P7 and P20 (Figure 3.3a).  However, by P60, 
ASC deletion significantly reduced CGNP hyperproliferation and reduced the proportion and 
thickness of EGL in the cerebella (Figures 3.3a and b).  Thus, ASC deficiency did not block the 
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initial stages of CGNP hyperproliferation but markedly diminished ectopic EGL in the 
cerebellum by P60. 
 
ASC deficient SmoA1 cerebella exhibit reduced proliferation 
Tumorigenesis can be regulated by the balance of proliferation, differentiation, and 
apoptosis.  We sought to determine which factors were responsible for the requirement of 
ASC in Shh-driven medulloblastoma.  To test whether proliferation was altered in the ASC 
knock-out cerebella in the medulloblastoma model, we performed Western blot analysis for 
cyclin D2 and immunohistochemistry for the mitotic marker pH3 in wild-type and ASC-
deficient SmoA1 mice.  Cyclin D2 levels were unchanged at P7, but were reduced by P20 
with ASC deficiency.  This difference was even more striking by P60, at which point cyclin D2 
levels were virtually undetectable in the ASC-deficient mice but were sustained in the wild-
type mice on the SmoA1 background (Figure 3.3d).  Thus, even though gross reduction in 
hyperplasia was not detected by P20 in the ASC-/-;SmoA1 cerebella, markers of proliferation 
showed an emerging trend of reduction at this time point.  To directly test whether ASC 
expression affected proliferation of the CGNPs in the EGL, we conducted pH3 
immunohistochemistry.  Consistent with the reduction in cyclin D2 levels, pH3 staining was 
also reduced by nearly 50 % at P20, revealing a lower mitotic frequency in the EGL with ASC 
deletion (Figures 3.3e and f).  These results identify a role for ASC in regulating ectopic 
proliferation of CGNPs in medulloblastoma.   
ASC RNA and protein levels were both high during the peak period of CGNP 
proliferation at P7 and decreased with cerebellar maturation during normal development 
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(Figure 3.1a), but continued to be expressed throughout development in the 
medulloblastoma model where CGNP proliferation persists (Figure 3.3d).  Previous studies 
have reported a decrease in proliferation with ASC deficiency in stimulated CD4+ and CD8+ 
T cells, splenocytes, and lymph node cells (Kolly et al., 2009; Ippagunta et al., 2010; Narayan 
et al., 2011).  However, other studies have reported either no difference in proliferation of 
ASC knock-out splenocytes or an increase in proliferation with ASC deletion in keratinocytes 
(Shaw et al., 2010; Drexler et al., 2012).  Together, these data point to a complex role for 
ASC in regulating cell proliferation, with our results showing that ASC deficiency markedly 
reduces proliferation in medulloblastoma. 
Numerous studies have shown that ASC is proapoptotic when overexpressed in 
cancer cell lines (Conway et al., 2000; Ohtsuka et al., 2004; Ohtsuka et al., 2006; Parsons 
and Vertino, 2006; Ramachandran et al., 2010; Hong et al., 2013).  Furthermore, knockdown 
of endogenous ASC reduces apoptosis of breast epithelial cells (Parsons et al., 2009), colon 
cancer cells (Hong et al., 2013), and osteosarcoma cells (Ohtsuka et al., 2004).  We 
examined whether ASC altered apoptosis or differentiation during tumorigenesis and found 
no statistical differences in the differentiation marker NeuN or the apoptosis marker 
cleaved caspase-3 between wild-type and ASC-deficient P20 SmoA1 EGL (Figures 3.3e and 
f).  Likewise, other groups have found no difference in apoptosis with loss of endogenous 
ASC in keratinocytes or splenocytes (Kolly et al., 2009; Drexler et al., 2012).  Together, these 
results identify reduced proliferation as the likely key factor suppressing medulloblastoma 
tumorigenesis in ASC deficient mice, as no significant differences in cell differentiation or 
apoptosis were observed between wild-type and ASC-deficient cerebella.   
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ASC deficient SmoA1 cerebella exhibit increased TGF-β signaling 
To determine the mechanism by which ASC deficiency inhibits proliferation in 
medulloblastoma, we conducted a microarray analysis comparing gene expression of ASC-/- 
versus ASC+/+ cerebella on the SmoA1 background.  We focused on P20 because the 
differences in the ASC-/- and ASC+/+ cerebellar phenotypes begin to emerge at this timepoint.  
Microarray data are available in Gene Expression Omnibus under the accession number 
GSE48682.  Microarray analysis revealed only 3 genes (in addition to ASC) to be 
differentially expressed between ASC-/- and ASC+/+ SmoA1 cerebellum at this timepoint 
(Table 3.1).  Of these, Tgfb1i1 (transforming growth factor beta-1-induced transcript 1), 
which was 2.5 fold higher in the ASC knock-out samples, is known to be upregulated with 
TGF-β (transforming growth factor-β) (Shibanuma et al., 1993).  Interestingly, Tgfb1i1 (also 
known as Hic-5) has been reported to inhibit cell proliferation when overexpressed in cells 
(Shibanuma and Nose, 1998; Dabiri et al., 2008).  We next examined whether the TGF-β 
pathway was altered in the absence of ASC.  Indeed, quantitative PCR analysis confirmed 
dysregulation of TGF-β pathway genes in the knock-out, with Tgfb1i1 significantly 
upregulated while the TGF-β inhibitor Tgif1 was significantly downregulated in ASC-
deficient P20 SmoA1 mice.  Furthermore, cell cycle genes cyclin D2 and Cdk2 were 
decreased in the ASC knock-out SmoA1 cerebella (Figure 3.4a). 
Dysregulation of the TGF-β pathway has been recognized in a subgroup of 
medulloblastomas (Cho et al., 2011; Aref et al., 2012; Northcott et al., 2012).  To investigate 
whether TGF-β signaling is altered in ASC-/- transgenic cerebella, we evaluated cellular 
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phospho-Smad3 localization using immunohistochemistry.  Interestingly, we found a greater 
percentage of cells with nuclear Smad3 in the ASC deficient SmoA1 transgenic cerebella 
(Figure 3.4b).  These data reveal an unexpected link between ASC and the TGF-β pathway 
whereby ASC deficiency results in an increase in signaling via the TGF-β pathway in a mouse 
model of medulloblastoma. 
Interestingly, TGF-β activation has a dual role in cancer, as the pathway promotes 
epithelial-mesenchymal transition and metastasis, but early TGF-β activation restricts 
tumorigenesis by inducing apoptosis and reducing cell proliferation (Rich, 2003; Massague, 
2008).  The dichotomous effects of the TGF-β pathway are evident in medulloblastoma.  
One group found disruption of TGF-β pathway genes in one of four subsets of 
medulloblastoma, namely deletion of TGF-β inhibitors and amplification of Type II activin 
receptors and TGFBR1 (Northcott et al., 2012).  In contrast, we observed an association 
between increased TGF-β pathway gene expression and signaling and decreased CGNP 
proliferation in the ASC knock-out SmoA1 P20 cerebella.  Consistent with our results, 
increasing TGF-β signaling with Smad5 overexpression in the presence of Shh stimulation 
reduces CGNP proliferation in vitro (Rios et al., 2004).  Furthermore, increased TGF-β 
signaling (e.g. increased nuclear Smad3) in SHH-related human medulloblastomas is 
correlated with a more favorable prognosis (Aref et al., 2012). 
While these results in medulloblastoma identify a clear role of ASC in promoting 
tumorigenesis, ASC has also been described as a tumor suppressor in specific cancer 
models.  ASC suppresses tumorigenesis in a colitis-associated colon cancer mouse model, 
where ASC deficiency enhanced polyp formation and clinical exacerbation, resulting in 
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reduced survival (Allen et al., 2010; Zaki et al., 2010).  In melanoma, ASC has a complex role 
in which selective deletion of ASC in bone marrow derived macrophages suppressed tumor 
number but ASC ablation in keratinocytes promoted tumorigenesis (Drexler et al., 2012).  
When ASC was deleted from the whole animal, ASC knock-out mice showed no differences 
from wild-type in melanoma susceptibility (Drexler et al., 2012).  A recent study found that 
ASC-deficient metastatic melanoma cells injected into nude mice displayed reduced tumor 
growth as compared to wild-type tumor cell implantation.  In contrast, ASC-deficient 
primary melanoma implants hastened tumor growth versus wild-type controls (Liu et al., 
2013).  Thus, the role of ASC in carcinogenesis appears to depend on cancer type and the 
stage of cancer progression.   
In summary, our results identify a critical function of ASC in driving proliferation and 
tumorigenesis in Shh pathway-driven models of medulloblastoma.  Improved therapeutics 
for this cancer are needed due to the high mortality and devastating side effects of current 
treatment.  Our results show that targeting ASC may be a promising strategy for preventing 
tumor progression of medulloblastoma. 
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3.4  Figures and Legends 
 
Figure 3.1.  ASC is expressed in cerebellum and medulloblastoma but ASC deficiency does 
not affect normal cerebellum development.   
 
(a) Western blot analysis of cerebellar lysates reveals ASC expression during normal 
cerebellum development and increased ASC expression in medulloblastoma.  (Tumor 
sample shown is from postnatal 101-day-old, P101, mouse.)  Densitometric quantification 
reveals ASC levels are increased in medulloblastomas.  Data are mean of at least three 
separate experiments +/- s.e.m. analyzed by Student’s t-test.  ASC levels are normalized to 
loading controls and average P60 levels were set to 1.0 for each experiment.  *P<0.05.  
Cerebella were collected at specified ages and lysates were probed with antibodies against 
ASC (Alexis Biochemicals, Lausen, Switzerland; Adipogen, San Diego, CA, USA), Cyclin D2 
(CD2; Cell Signaling, Danvers, MA, USA) and α-tubulin (Sigma-Aldrich, St. Louis, MO, USA).  
(b) Quantitative RT-PCR analysis demonstrates ASC mRNA decreases during normal 
cerebellum development and is induced in medulloblastoma.  Cerebella were collected at 
the ages specified (n≥4 per age).  Tumors were collected at an average age of P138 (P101-
P205; n=8).  qRT-PCR was conducted similarly as previously described (Kole et al., 2011), 
using ASC primers Pycard-FW: 5’-GACCAGCACAGGCAAGCA-3’, Pycard-Rev: 5’-
TCCAGCACTCCGTCCACTTC-3’, Gapdh-FW: 5’-TGTGTCCGTCGTGGATCTGA-3’, and Gapdh-Rev: 
5’-CCTGCTTCACCACCTTCTTGA-3’, and normalizing to GAPDH levels.  Data are mean ± s.e.m 
analyzed by the Mann-Whitney test.   Experiments were done in triplicate at least three 
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times.   **P<0.01;  *P<0.05.  (c) Oncomine analysis of independent gene profiling studies, 
with data from Kool et al. (Kool et al., 2008) and Fattet et al. (Fattet et al., 2009) used to 
compare ASC mRNA expression levels in classic versus desmoplastic human primary 
medulloblastomas.  Each dataset had equivalent proportions of desmoplastic tumors (22%) 
and classic tumors (78%) and F-test analysis determined the datasets did not have unequal 
variance (F=0.054).  Each dataset mean was adjusted to zero to correct for technical bias 
between datasets.  Data are median, minimum to maximum values (*, P=0.025, two-tailed 
t-test, F-test=0.054.  n=74 classic; n=21 desmoplastic).  (P=0.047 in comparison of 
unadjusted data.)  (d) Representative images of H&E stained sagittal sections of ASC+/+ and 
ASC-/- cerebella at specified ages show no differences in gross cerebellar architecture with 
development between genotypes (n≥3 per group).  Scale bars represent 1 mm and 200 µm 
(inset).  (e) ASC+/+ and ASC-/- cerebellar lysates at specified ages were immunoblotted as 
described above.  (f) Immunohistochemistry (IHC) for phospho-histone H3 (pH3; Cell 
Signaling) in P7 ASC+/+ and ASC-/- sagittal cerebellar sections.  Quantitative comparison of 
cells expressing pH3 in ASC+/+ and ASC-/- EGL (n≥3 per group).  The EGL region was manually 
annotated using Aperio ImageScope V12 and analyzed with Aperio Nuclear V9 Algorithm 
(Aperio Technologies, Inc., Vista, CA, USA).  The data represent mean +/- s.e.m. analyzed by 
Student’s t-test.  Scale bar represents 200 µm.   
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Figure 3.1 
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Figure 3.1 continued 
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Figure 3.2.  ASC deficiency suppresses medulloblastoma tumorigenesis in the SmoA1 and 
SmoM2 mouse models.   
 
(a) Kaplan-Meier analysis of ASC+/+;SmoA1 mice (n=15), ASC+/-;SmoA1 mice (n=34), and ASC-
/-;SmoA1 mice (n=18) reveals a significant difference in tumor incidence with ASC expression 
(P=0.0019; Log-Rank test).   ASC deficiency significantly decreased tumor frequency and 
increased tumor latency when compared to ASC+/+;SmoA1 (P=0.0004; Log-Rank test) and 
ASC+/-;SmoA1 mice (P=0.0077; Log-Rank test).   (P=0.1108 between ASC+/-;SmoA1 and 
ASC+/+;SmoA1 mice; Log-Rank test.)  (b) Overall incidence of medulloblastoma by P270 is 
reduced in ASC-/-;SmoA1 versus ASC+/+;SmoA1 (P=0.0049) and ASC+/-;SmoA1 (P=0.0088) 
mice; **P<0.01 (Fisher’s exact test). (c)  Kaplan-Meier analysis of ASC+/+;SmoM2 mice (n=4), 
ASC+/-;SmoM2 mice (n=9), and ASC-/-;SmoM2 mice (n=6) reveals a significant difference in 
tumor incidence with ASC expression (P= 0.0004; Log-Rank test).  ASC+/+;SmoM2 mice 
displayed shorter tumor latency than either ASC-/-;SmoM2 (P=0.0025; Log-Rank test) or 
ASC+/-;SmoM2 (P=0.0003; Log-Rank test) mice.  (P=0.7317 between ASC+/-;SmoM2 and ASC-/-
;SmoM2 mice; Log-Rank test.)  (d)  Average age mice become moribund is increased with 
ASC deficiency in ASC-/-;SmoM2 mice and ASC+/-;SmoM2 mice.  **P=0.004; *P=0.025 
(Student’s t-test).  (e) IL-1β deficiency does not affect tumorigenesis in the SmoA1 
medulloblastoma model.  Kaplan-Meier analysis of IL-1β+/+;SmoA1 mice (n=19), IL-1β+/-
;SmoA1 mice (n=59), and IL-1β-/-;SmoA1 mice (n=11) reveals no difference in tumorigenesis 
with IL-1β expression (P=0.792; Log-Rank test).  (f) Overall incidence of medulloblastoma by 
P270 is unaffected by IL-1β deficiency (Fisher’s exact test). 
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Figure 3.2 
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Figure 3.3.  ASC deficiency reduces proliferation in the SmoA1 cerebella.  
 
(a)  Representative H&E stained sagittal sections of ASC+/+;SmoA1 and ASC-/-;SmoA1 
cerebella at specified ages reveals reduced EGL with ASC deficiency.  Scale bars represent 1 
mm and 200 µm (inset).  EGL was quantified at P7, P20, and P60 by (b) EGL area in 
proportion to cerebellum (CB) area and (c) maximum EGL thickness in ASC+/+;SmoA1 and 
ASC-/-;SmoA1 cerebella at the specified ages (n≥3 per group).  ASC deficiency reduced EGL 
area proportion and maximum EGL thickness in P60 cerebella.  **P=0.0049;*P=0.045 
(Student’s t-test).  ASC status significantly altered both EGL proportion and thickness over 
all timepoints (P=0.035 and P=0.04 respectively; two-way ANOVA).  (d) Western blot 
analysis of ASC+/+;SmoA1 and ASC-/-;SmoA1 cerebellar lysates at the specified ages as 
described above.   Densitometric quantification at P60 reveals Cyclin D2 (CD2) levels are 
reduced with ASC deficiency.  Data are mean +/- s.e.m. analyzed by Student’s t-test (n≥5 per 
group).  ***P=0.00039.  (e) IHC for pH3, NeuN (Millipore, Billerica, MA, USA), and cleaved 
caspase-3 (CC3; Biocare Medical, Concord, CA, USA) of P20 ASC+/+;SmoA1 and ASC-/-;SmoA1 
cerebella (n≥3 per group).  Scale bar represents 200 µm.  (f) Quantification of positively 
stained cells in the P20 EGL reveals a significant decrease in pH3 staining with ASC 
deficiency.  *P= 0.017.  The data represent mean +/- s.e.m. analyzed by Student’s t-test (n≥3 
per group). 
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Figure 3.3 
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Figure 3.3 continued 
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Table 3.1.  Summary of genes differentially expressed with ASC deficiency in P20 SmoA1 
cerebella. 
 
Total RNA was purified from P20 SmoA1 cerebella (n=5, ASC+/+;SmoA1; n=4, ASC-/-;SmoA1) 
and 1000 ng RNA per sample was labeled using the Quick Amp Labeling Kit (Agilent 
Technologies, Sugar Land, TX, USA) and hybridized on two-color whole mouse genome 
4x44K microarrays (Agilent Technologies).  1000 ng RNA from pooled P16 wild-type 
cerebella was amplified and labeled with Cy3 as a reference for each sample.  Raw data was 
processed and analyzed by GeneSpring GX Version 11.0 (Agilent Technologies).  Genes with 
a corrected P value <0.05 following unpaired t-test and Benjamini and Hochberg false 
discovery rate procedure were considered differentially expressed. 
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Table 3.1 
 
Symbol   
 
RefSeq 
 
Gene Name  
 
Fold 
change  
P 
value  
Up-regulated    
Gdpd3  
 
NM_024228  
 
Glycerophosphodiester phospho-
diesterase domain containing 3  
+5.914 
  
0.0268 
 
Tgfb1i1 
 
NM_009365  
    
Transforming growth factor beta 1 
induced transcript 1  
+2.504  
 
0.0494 
 
Down-regulated    
Sec23ip  NM_001029982 Sec23-interacting protein  -1.492 0.0268 
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Figure 3.4.  ASC deficiency alters the TGF-β pathway in SmoA1 cerebella.   
 
(a) Quantitative RT-PCR analysis reveals several genes in the TGF-β pathway are 
differentially expressed in ASC-/- versus ASC+/+ P20 SmoA1 cerebella.  qRT-PCR was 
conducted similarly as previously described (Kole et al., 2011), using primers Tgfb1-FW: 5’-
ACCATGCCAACTTCTGTCTG-3’ and Tgfb1-Rev: 5’-CGGGTTGTGTTGGTTGTAGA-3’; Tgfb1i1-FW: 
5’-CCTTTTCGCCCCGAGTGCTA-3’ and Tgfb1i1-Rev: 5’-CGGATGGGTTGGTTACAGAAG-3’; Tgif1-
FW: 5’-GAGGATGAAGACAGCATGGA-3’ and Tgif1-Rev: 5’-TTCTCAGCATGTCAGGAAGG-3’; 
Cyclin D2-FW: 5’-TCGATGATTGCAACTGGAAG-3’ and Cyclin D2-Rev: 5’-
AGAGCTTCGATTTGCTCCT-3’; and Cdk2-FW: 5’-TCATGGATGCCTCTGCTCTCAC-3’ and Cdk2-
Rev: 5’-TGAAGGACACGGTGAGAATGGC-3’; Gapdh-FW: 5’-TGTGTCCGTCGTGGATCTGA-3’ and 
Gapdh-Rev: 5’-CCTGCTTCACCACCTTCTTGA-3’, and normalizing to GAPDH levels.  Data are 
mean ± s.e.m analyzed by the Mann-Whitney test.   Experiments were done in triplicate at 
least three times (n≥3 per genotype).  **P<0.01;  *P<0.05.  (b) Quantification of Smad3 IHC 
(Abcam, Cambridge, MA, USA) in P20 ASC+/+;SmoA1 and ASC-/-;SmoA1 cerebella reveals an 
increase in cells positive for nuclear Smad3.  50 μm wide bands of the outer internal 
granular layer and molecular layer were analyzed and Purkinje cells were excluded from the 
analysis.  *P<0.05.  The data represent mean +/- s.e.m. analyzed by Student’s t-test (n≥3 per 
group). 
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Figure 3.4 
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CHAPTER IV:  DISCUSSION 
 
4.1  Summary of Findings 
 While the brain has long been considered an immunoprivileged region, our 
perceptions are shifting to recognize that immune genes play important roles in neurons 
and the nervous system.  Research is revealing the unexpected results that neurons express 
immune genes such as complement and toll-like receptors (TLRs), and now, the NLRs and 
inflammasome genes.  Surprisingly, the role of immune molecules in neurons varies from 
neuronal or immune functions to no known function.  For instance, complement proteins 
direct synapse elimination in developing brain (Stevens et al., 2007) and TLR-3 activation 
can suppress axonal growth (Cameron et al., 2007) or reduce HSV-1 infection (Zhou et al., 
2009).  Furthermore, cytokines produced by immune cells can influence neuron-specific 
characteristics, such as IL-2 regulating neurite outgrowth of sympathetic neurons (Haugen 
and Letourneau, 1990).  In turn, sympathetic nerves of the peripheral nervous system can 
regulate the immune system by modulating cytokine release and immune cell recruitment 
into target organs (Madden et al., 1994; Li et al., 2004).  Finally, immune genes can regulate 
tumorigenesis, as has been shown with ASC promoting metastatic melanoma (Liu et al., 
2013) and colon cancer (Allen et al., 2010).  This dissertation work is the first to investigate 
the role of ASC expression on a cancer of the nervous system and also the first to elucidate 
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how the sympathetic neuron apoptotic pathway is affected by interferon-gamma. Thus, we 
are in a nascent stage in a burgeoning field at the crossroads of neurobiology and 
immunology.  The findings from this dissertation are summarized below.   
 
 
Interferon-gamma protects sympathetic neurons from apoptosis at the point of cytochrome 
c release:   
1. Whereas IFN-γ induces apoptosis in many cell types, IFN-γ protects sympathetic 
neurons from apoptosis induced by nerve growth factor (NGF) deprivation or 
pan-kinase inhibition.  
2. The inhibition of apoptosis by IFN-γ occurs at the point of mitochondrial 
permeabilization. 
3. IFN-γ does not change neuron death with cytochrome c injection, revealing that 
it does not directly act downstream of mitochondrial permeabilization. 
4. Despite inhibiting apoptosis in neurons, IFN-γ induces upregulation of interferon-
stimulated genes and proapoptotic genes in sympathetic neurons. 
5. Many proapoptotic genes that are induced by interferon in other cell types are 
not induced by IFN-γ in sympathetic neurons. 
 
ASC deficiency suppresses proliferation and prevents medulloblastoma incidence: 
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1.  ASC, which is silenced by promoter methylation in many cancers, is upregulated 
at the RNA and protein level in a Sonic hedgehog-driven model of 
medulloblastoma. 
2. ASC is expressed in human medulloblastomas and its expression is increased in 
Sonic hedgehog-driven tumors over classic tumors. 
3. ASC knock-out cerebella on a non-tumor background display gross architecture 
and proliferation markers similar to wild-type. 
4. ASC deficient ND2:SmoA1 mice exhibit a profound reduction in medulloblastoma 
incidence and a delayed tumor onset. 
5. ASC heterozygous and knock-out GFAP-Cre:SmoM2 mice display a markedly 
extended survival. 
6. IL-1β deficiency does not affect tumorigenesis in the SmoA1 model. 
7. Premalignant lesions in cerebella of ASC-/-;ND2:SmoA1 mice displayed a striking 
decrease in number of ectopic progenitors. 
8. Markers of proliferation, but not apoptosis or differentiation, decreased with 
ASC deletion in ND2:SmoA1 cerebella. 
9. ASC deficiency disrupted expression of genes in the TGF-β pathway and 
increased the level of nuclear Smad3 in the SmoA1 model. 
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4.2  Discussion of the Major Findings and Future Directions 
 
 
Interferon-gamma protects sympathetic neurons from apoptosis at the point of cytochrome 
c release 
During infection, injury, or tumors, interferons (IFNs) are produced and released by 
cells to inhibit pathogen replication, regulate immune cells, modulate cell growth, 
proliferation, and differentiation, and induce cell death (Chawla-Sarkar et al., 2003; Maher 
et al., 2007).  Interferons are considered apoptosis-inducing cytokines (Schroder et al., 
2004) and induce apoptosis and other forms of cell death in many cell types (Dijkmans et 
al., 1990; Baerwald and Popko, 1998; Barber, 2000; Becher et al., 2000; Chawla-Sarkar et al., 
2003; Clemens, 2003; Schroder et al., 2004; Pokrovskaja et al., 2005; Maher et al., 2007; 
Zhang et al., 2008; Das et al., 2009) to limit the spread of infection (Dafny and Yang, 2005; 
Maher et al., 2007).  Sympathetic neurons of the peripheral nervous system may be 
particularly exposed to infectious microorganisms and immune cells, as some pathogens 
first invade sensory nerves and spread to the brain via centripetal axonal transport 
(Rottenberg and Kristensson, 2002). 
In this research, we show that the effect of IFN-γ on sympathetic neurons is 
completely the opposite of what is seen in other cell types.  Not only does IFN-γ fail to 
induce apoptosis, but it suppresses apoptosis in sympathetic neurons treated with NGF 
deprivation or pan-kinase inhibition (Fig. 2.1).  We have probed the apoptotic pathway in 
IFN-γ-treated sympathetic neurons and found that IFN-γ inhibited the events that occur 
after the point of mitochondrial permeabilization including cytochrome c release and 
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caspase-3 activation but didn’t change the early events of c-Jun phosphorylation or BH3-
only protein induction (Fig. 2.2).  Thus, IFN-γ acts at the point of mitochondrial 
permeabilization, likely through inhibition of Bax activation, to suppress the intrinsic 
apoptotic pathway in NGF-deprived sympathetic neurons.  Cytochrome c injection 
experiments also revealed that IFN-γ does not inhibit apoptosis after the point of 
mitochondrial permeabilization in sympathetic neurons (Fig. 2.3).  Interestingly, gene array 
analysis showed that IFN-γ upregulates several proapoptotic genes in sympathetic neurons, 
but this induction is insufficient to cause apoptosis in these cells (Table 2.3).  Finally, IFN-γ 
did not induce expression of a number of proapoptotic genes in sympathetic neurons as it 
does in other cell types (e.g. Fas, FADD, caspases) (Table 2.3).  Overall, these findings 
demonstrate that sympathetic neurons, unlike most cell types, respond to interferon by 
suppressing the apoptotic pathway.  Thus, IFN-γ promotes survival of these terminally 
differentiated sympathetic neurons, which must persist for the lifetime of the organism. 
The data presented in this dissertation pinpoints mitochondrial permeabilization as 
the step in the apoptotic pathway which IFN-γ inhibits in NGF-deprived sympathetic 
neurons.  Our hypothesis is that IFN-γ acts directly at the point of Bax activation to inhibit 
neuronal apoptosis.  One approach to test this hypothesis is as follows.  In the extrinsic 
apoptotic pathway, Bid is cleaved by active caspase-8 into tBid, which then induces the 
oligomerization of Bax at the mitochondria, forming a pore in the outer membrane (Eskes et 
al., 2000; Grinberg et al., 2002).  Thus, tBid can be used as a tool to directly trigger Bax 
activation in cells.  We will perform microinjection of truncated Bid (tBid) into sympathetic 
neurons with or without IFN-γ and assess cytochrome c release.  If IFN-γ suppresses Bax 
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activation, tBid injection will result in reduced Bax activation and cell death with IFN-γ.  An 
alternative approach to this question would be to inject GFP-Bax plasmid into neurons with 
pan-caspase inhibitor QVD-OPH.  GFP-Bax translocates from a diffuse cytosolic expression 
to a punctate pattern at the mitochondria upon activation (Wolter et al., 1997).  
Microinjection of this plasmid into sympathetic neurons treated with or without IFN-γ will 
result in similar or differential Bax localization and activation, revealing whether IFN-γ 
suppresses Bax activation.   
Our data show that levels of Bax, Bcl-XL, Bim, and Puma are unchanged with IFN-γ 
(Fig. 2.2), thus future research is needed to determine the exact mechanism by which IFN-γ 
suppresses mitochondrial permeabilization in sympathetic neurons.  Several candidates not 
yet examined here have previously been shown to affect Bax activation.  For example, we 
will examine levels of another BH3-only protein, Mcl-1, which may be regulated by protein 
kinase casein kinase 2  (Chang and Chao, 2013).  Another candidate is Ku70, which binds Bax 
to sequester it from the mitochondria and prevent mitochondrial permeabilization (Cohen 
et al., 2004).  Furthermore, while Bim and Bmf are induced by phospho-c-Jun during 
apoptosis, phosphorylation of these BH3-only proteins may free them from sequestration at 
dynein motor complexes, allowing engagement in the apoptotic pathway (Lei and Davis, 
2003).  Thus, we will examine whether IFN-γ decreases the phosphorylation of Bim and Bmf, 
reducing their ability to activate Bax. 
We found HIN-200 gene ifi202b to be highly induced in sympathetic neurons with 
IFN-γ treatment (Fig. 2.4).  ifi202b encodes p202, which binds and inhibits several 
transcription factors, including c-Jun, c-Fos, c-Myc, NF-κB, E2F2, and p53 (Min et al., 1996; 
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Asefa et al., 2004; Choubey and Panchanathan, 2008; Mondini et al., 2010).  p202 can 
enhance or diminish apoptosis in cells depending on which transcription factors are active 
in each cell type (Choubey and Panchanathan, 2008).  While c-Jun induction and 
phosphorylation was unchanged by IFN-γ in NGF-deprived sympathetic neurons (Fig. 2.2), it 
is possible IFN-γ could act through p202 to regulate the activity of other transcription 
factors, such as NF-κB or E2Fs, which regulate sympathetic neuron survival (Maggirwar et 
al., 1998; Wright et al., 2007).  We found that microinjection of ifi202b plasmid or sh-ifi202b 
into neurons did not affect apoptosis with NGF deprivation (data not shown).  However, 
since levels of p202 are constitutively high in neurons compared to other cell types (data 
not shown), overexpression or IFN-γ induction of p202 may not confer additional 
protection.  Methodologically, the individual cell assay of microinjection experiments only 
allows for evaluation of cellular expression by immunofluorescence, and the p202 antibody 
had not been tested in knock-out cells.  Future experiments should utilize sympathetic 
neurons from a p202 knock-out organism to assess the importance of p202 in modulating 
neuronal survival. 
The data presented here show that sympathetic neurons respond to IFN-γ by 
upregulating an array of genes including interferon-stimulated genes and also several genes 
(e.g. Trail, Irf1, Irf8, and PKR), which promote activation of the extrinsic apoptotic pathway 
(Table 2.2 and 2.3) (Barber, 2000; Chawla-Sarkar et al., 2003; Clemens, 2003; Schroder et 
al., 2004; Pokrovskaja et al., 2005).  The induction of proapoptotic genes was insufficient to 
reduce survival of sympathetic neurons, however, perhaps due to these cells being resistant 
to apoptosis induced by death receptor ligands (Marz et al., 1996).  No anti-apoptotic genes 
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were identified in the unbiased gene array (Table 2.2).  Importantly, sympathetic neurons 
did not upregulate many of the proapoptotic genes reported to be induced by interferon in 
other cell types, revealing a differential response in these neurons (Table 2.3).  We are 
currently quantitatively comparing IFN-γ-induced gene expression between sympathetic 
neurons and other cell types using publically available microarray data on Gene Expression 
Omnibus (GEO).  The findings will reveal which of the tens of thousands of genes are 
differentially expressed in neurons versus other cell types, illuminating neuron-specific gene 
induction in response to IFN-γ. 
 
IFN-γ promoting neuronal survival:  possible physiological implications 
Sympathetic neurons are vulnerable to apoptosis during development but resistant 
during maturity (Kole et al., 2011).  The data presented here indicate that IFN-γ protects 
developing sympathetic neurons from apoptosis.  The ability of IFN-γ to inhibit neuronal 
apoptosis could be a physiological mechanism that protects neurons from the harmful 
effects of immune cell activation, infection, or injury during development.  Sympathetic 
neurons of the peripheral nervous system may be particularly exposed to infectious 
microorganisms, as some pathogens first invade sensory nerves and spread to the brain via 
centripetal axonal transport (Rottenberg and Kristensson, 2002).  In addition to inhibiting 
replication of neurotrophic viruses and bacteria, such as Listeria monocytogenes 
(Rottenberg and Kristensson, 2002), IFN-γ protects against neuronal death from herpes 
simplex virus-1 (Geiger et al., 1997), Sindbis virus (Burdeinick-Kerr et al., 2009), and Borna 
disease virus (Richter et al., 2009).  IFN-γ is secreted by macrophages, NK cells, and T 
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lymphocytes, which are recruited to the site of infection or injury (Chawla-Sarkar et al., 
2003; Schroder et al., 2004).  IFN-γ activates macrophages, which then release molecules 
such as nitric oxide radicals that can kill pathogens, but could also inadvertently trigger 
sympathetic neuron death (Arantes et al., 2000; Rottenberg and Kristensson, 2002; 
Almeida-Leite et al., 2007).  Similarly, stimulated T or NK cells can promote DRG and 
hippocampal neuron death (Rottenberg and Kristensson, 2002; Yong et al., 2007).  IFN-γ 
protects neurons from activated macrophages, T lymphocytes, and NK cells, indicating that 
IFN-γ counteracts cytotoxic signals from the immune cells in the neurons’ milieu 
(Burdeinick-Kerr et al., 2009; Richter et al., 2009).  Thus, control of infection depends on 
recruitment and activation of immune cells which produce IFN-γ that both inhibits 
microorganisms and protects neurons from death.  Disruption of IFN-γ signaling can 
therefore render the nervous system vulnerable to infection.  For example, 
immunodeficiency disorders such as Human Immunodeficiency Virus (HIV) are characterized 
by disruption of immune cells, leading to lower IFN-γ and increased susceptibility to 
infections (Koirala et al., 2008).  Therefore, clinical administration of IFN-γ may be 
advantageous in certain immunodeficient individuals to prevent infection and protect 
developing sympathetic neurons from cell death.  Since IFN-γ can induce cell death of many 
cell types, including cortical neurons (Dedoni et al., 2012), IFN-γ administration should be 
localized to the site of infection in treated individuals.  Finally, it remains to be seen 
whether IFN-γ can be an effective therapeutic for disorders of mature neuron degeneration, 
for instance in HIV-related neuropathies of the peripheral nervous system (Kamerman et al., 
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2012), which are characterized by macrophage-induced loss of DRG neurons (Pardo et al., 
2001). 
 
ASC deficiency suppresses proliferation and prevents medulloblastoma incidence: 
ASC, also known as TMS-1, target of methylation-induced silencing-1, is silenced by 
promoter methylation in many types of cancers (Conway et al., 2000; Guan et al., 2003; 
Alaminos et al., 2004; Stone et al., 2004; Machida et al., 2006)  Ectopic ASC expression 
induces cell death (Conway et al., 2000; Ohtsuka et al., 2004; Ohtsuka et al., 2006; Parsons 
and Vertino, 2006; Ramachandran et al., 2010; Hong et al., 2013), while knock down of 
endogenous ASC inhibits apoptosis in several cell types (Ohtsuka et al., 2004; Parsons et al., 
2009; Hong et al., 2013).  Furthermore, ASC is the adaptor protein for the inflammasome, 
which when activated can induce cell death (Satoh et al., 2013).  Due to ASC’s pro-death 
functions, ASC has been considered a tumor suppressor in several cancers.    
The data presented here reveal the unexpected results that ASC potently promotes 
tumorigenesis in two Sonic hedgehog-driven models of medulloblastoma, the most 
common malignant pediatric brain cancer (Hatten and Roussel, 2011).  ASC was expressed 
at high levels in tumors and ASC deficiency robustly suppressed medulloblastoma incidence 
and delayed age of tumor onset (Fig. 3.1, 3.2).  ASC deficient mice displayed reduced 
premalignant lesions as well as EGL proliferation, while EGL apoptosis and differentiation 
remained unchanged (Fig. 3.3).  Furthermore, ASC deficiency led to an increase in cerebellar 
TGF-β pathway expression and signaling (Fig. 3.4).   
Interestingly, although ASC had a profound effect on medulloblastoma incidence, 
ectopic EGL volume, and proliferation, there was no discernible difference between ASC 
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knock-out and wild-type on the non-tumor background in gross cerebellar architecture or 
proliferation (Fig. 3.1).  Thus, ASC is not required for normal cerebellum development but is 
necessary for cerebellum cancer development.  These findings reveal a requirement of ASC 
in hyperproliferation but not normal proliferation of CGNPs.  Further research is needed to 
elucidate the mechanisms underlying these differences.  
ASC promotes proliferation markers in the ectopic EGL in the medulloblastoma 
model.  To examine whether the effects of ASC in CGNP proliferation was cell autonomous, 
we cultured CGNPs from ASC wild-type or ASC knock-out mice and compared cyclin D2 
expression using Western blotting.  Surprisingly we found that cyclin D2 levels were 
equivalent regardless of ASC expression in this cell culture model (data not shown).  This 
finding suggests that ASC expression may not have a cell-autonomous effect on CGNP 
proliferation.  ASC is a ubiquitously expressed gene and is known to be expressed in 
astrocytes and microglia.  Therefore, other cell types that secrete factors to regulate CGNP 
proliferation may be impacted by ASC expression.  For instance, astrocyte-secreted GDNF 
(glial cell line- derived neurotrophic factor) increases proliferation of neural progenitors in 
the hippocampus (Chen et al., 2005). 
Our research shows that ASC modulates expression of genes in the TGF- β pathway 
(Table 3.1).  ASC has a CARD and PYRIN domain, which are protein interacting domains that 
allow it to bind caspases, NLRs, and other proteins via homotypic CARD or PYRIN domain 
binding.  Through protein-protein interactions with IKKα and IKKβ through the PYRIN 
domain, ASC has been shown to bind and enhance or inhibit transcription factor activity of 
NF-κB (Stehlik et al., 2002).  Thus, there is precedent for ASC regulating gene expression 
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indirectly.  Determining how ASC is regulating expression of TGF-β pathway genes is a 
promising area for further research.  Furthermore, TGF-β signaling is dysregulated in many 
disorders, including muscular dystrophy (Ceco and McNally, 2013), glaucoma (Prendes et 
al., 2013), and many cancers, where it promotes epithelial-mesenchymal transition (EMT) to 
drive metastasis (Katsuno et al., 2013).  It will be interesting to see if ASC modulates the 
TGF-β pathway in these disease states as well.  
In addition to other functions, ASC is the adaptor protein of the inflammasome, a 
cytosolic complex that responds to pathogen or danger-associated molecules by activating 
Caspase-1, which then activates its substrates including IL-1β and IL-18.  To test whether 
ASC’s role in promoting medulloblastoma was inflammasome-dependent, we tested 
whether Caspase-1 or IL-1β expression altered tumor incidence similarly to ASC expression.  
IL-1β knock-out ND2:SmoA1 mice exhibited equivalent tumor incidence and rate of 
tumorigenesis as IL-1β+/+;ND2:SmoA1 mice (data not shown), demonstrating that ASC’s 
effects on medulloblastoma are independent of IL-1β.  Results for Caspase-1 are pending 
and will determine whether ASC requires Caspase-1 and the inflammasome in this model.  If 
ASC is acting via the inflammasome to promote tumorigenesis in medulloblastoma, clinical 
consideration should be given to avoid chemotherapeutics such as gemcitabine and 5-
fluorouracil which activate the inflammasome (Bruchard et al., 2013).   
Tumors consist of regions of apoptotic and necrotic cells which release ATP, 
triggering activation of the NLRP3 inflammasome (Ghiringhelli et al., 2009).  Inflammasome 
activation stimulates and recruits immune cells to the site of activation.  It is possible that 
dying cells in medulloblastomas also trigger inflammasome activation, which may result in 
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immune cell recruitment.  Our research reveals that medulloblastoma tumors are 
characterized by enhanced astrocyte and microglial recruitment and activation, as 
compared to non-tumor cerebellum.  We found no difference in astrocyte or microglial 
activation in fully developed ASC-/- tumors, however there was reduced astrocyte activation 
and fewer microglia in the P20 ASC knock-out ND2:SmoA1 EGL (data not shown).  The 
influence of these cell types has not been studied in medulloblastoma, thus how the 
activation of these cells influence medulloblastoma progression remains an unexplored and 
intriguing area for future study.   
We found ASC deficiency decreased markers of proliferation, cyclin D2 and pH3, in 
ectopic EGL in a medulloblastoma model (Fig. 3.3), however, ASC deletion has varied effects 
on tumor growth in other cancers.  In a model of melanoma, ASC deficiency of metastatic 
melanoma cells was determined to decrease tumor growth upon implantation into nude 
mice (Liu et al., 2013).  However, the same study found ASC knock down in primary 
melanoma cells to hasten tumor growth versus wild-type controls (Liu et al., 2013).  
Furthermore, ASC deletion in macrophages suppressed tumor number but ASC silencing in 
keratinocytes spurred tumorigenesis (Drexler et al., 2012).  In colitis-associated colon 
cancer, ASC deficiency clearly enhanced tumor formation and progression (Allen et al., 
2010; Zaki et al., 2010).  These studies reveal a complex role for ASC in tumorigenesis which 
depends on the cancer, the type of cells expressing ASC, and the stage of tumor 
progression.  These findings reveal that ASC, like TGF-β, can either suppress or promote 
tumorigenesis. 
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The discovery of a gene that has such a stark effect on medulloblastoma 
tumorigenesis is very rare and promising.  Based on the data presented here, we propose 
ASC as a promising target for cancer therapeutics.  Current treatments of medulloblastoma 
have devastating side effects and, even with treatment, mortality remains high for this 
disease (Polkinghorn and Tarbell, 2007).  Targeted gene therapy to knock down ASC 
expression in tumors and surrounding areas may prove effective in reducing growth or 
metastasis of medulloblastoma. 
  
 107 
 
REFERENCES 
 
Acehan, D., X. Jiang, D. G. Morgan, J. E. Heuser, X. Wang and C. W. Akey (2002). Three-
dimensional structure of the apoptosome: implications for assembly, procaspase-9 
binding, and activation. Mol Cell 9(2): 423-432. 
Aebischer, J., P. Cassina, B. Otsmane, A. Moumen, D. Seilhean, V. Meininger, L. Barbeito, B. 
Pettmann and C. Raoul (2011). IFNgamma triggers a LIGHT-dependent selective 
death of motoneurons contributing to the non-cell-autonomous effects of mutant 
SOD1. Cell Death Differ 18(5): 754-768. 
Alaminos, M., V. Davalos, N. K. Cheung, W. L. Gerald and M. Esteller (2004). Clustering of 
gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl 
Cancer Inst 96(16): 1208-1219. 
Allen, I. C., E. M. TeKippe, R.-M. T. Woodford, J. M. Uronis, E. K. Holl, A. B. Rogers, H. H. 
Herfarth, C. Jobin and J. P. Y. Ting (2010). The NLRP3 inflammasome functions as a 
negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 
207(5): 1045-1056. 
Almeida-Leite, C. M., L. M. Galvao, L. C. Afonso, F. Q. Cunha and R. M. Arantes (2007). 
Interferon-gamma induced nitric oxide mediates in vitro neuronal damage by 
Trypanosoma cruzi-infected macrophages. Neurobiol Dis 25(1): 170-178. 
Apte, R. N., Y. Krelin, X. Song, S. Dotan, E. Recih, M. Elkabets, Y. Carmi, T. Dvorkin, R. M. 
White, L. Gayvoronsky, S. Segal and E. Voronov (2006). Effects of micro-
environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour 
invasiveness and tumour-host interactions. European J Cancer 42(6): 751-759. 
Arantes, R. M., S. Lourenssen, C. R. Machado and M. G. Blennerhassett (2000). Early 
damage of sympathetic neurons after co-culture with macrophages: a model of 
neuronal injury in vitro. Neuroreport 11(1): 177-181. 
Aref, D., C. J. Moffatt, S. Agnihotri, V. Ramaswamy, A. M. Dubuc, P. A. Northcott, M. D. 
Taylor, A. Perry, J. M. Olson, C. G. Eberhart and S. E. Croul (2012). Canonical TGF-
beta Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and 
Delineates Putative Precursors in Cerebellar Development. Brain Pathol 23(2): 178-
191. 
Asefa, B., K. D. Klarmann, N. G. Copeland, D. J. Gilbert, N. A. Jenkins and J. R. Keller (2004). 
The interferon-inducible p200 family of proteins: a perspective on their roles in cell 
cycle regulation and differentiation. Blood Cells Mol Dis 32(1): 155-167. 
 108 
 
Baerwald, K. D. and B. Popko (1998). Developing and mature oligodendrocytes respond 
differently to the immune cytokine interferon-gamma. J Neurosci Res 52(2): 230-
239. 
Barber, G. N. (2000). The interferons and cell death: guardians of the cell or accomplices of 
apoptosis? Semin Cancer Biol 10(2): 103-111. 
Becher, B., A. Prat and J. P. Antel (2000). Brain-immune connection: immuno-regulatory 
properties of CNS-resident cells. Glia 29(4): 293-304. 
Bernabei, P., A. Allione, L. Rigamonti, M. Bosticardo, G. Losana, I. Borghi, G. Forni and F. 
Novelli (2001). Regulation of interferon-gamma receptor (INF-gammaR) chains: a 
peculiar way to rule the life and death of human lymphocytes. Eur Cytokine Netw 
12(1): 6-14. 
Bernabei, P., E. M. Coccia, L. Rigamonti, M. Bosticardo, G. Forni, S. Pestka, C. D. Krause, A. 
Battistini and F. Novelli (2001). Interferon-gamma receptor 2 expression as the 
deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol 
70(6): 950-960. 
Boselli, D., J. Ragimbeau, L. Orlando, P. Cappello, M. Capello, C. Ambrogio, R. Chiarle, G. 
Marsili, A. Battistini, M. Giovarelli, S. Pellegrini and F. Novelli (2010). Expression of 
IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma 
signaling and apoptosis in human T lymphocytes. Immunol Lett 134(1): 17-25. 
Boucher, D. and J. Denault (2012). Caspase Family. Sherbrooke, Springer. 
Bruchard, M., G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux, F. Vegran, W. Boireau, B. 
Simon, B. Ryffel, J. L. Connat, J. Kanellopoulos, F. Martin, et al. (2013). 
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells 
activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1): 57-
64. 
Bruckner, S. R., S. P. Tammariello, C. Y. Kuan, R. A. Flavell, P. Rakic and S. Estus (2001). JNK3 
contributes to c-Jun activation and apoptosis but not oxidative stress in nerve 
growth factor-deprived sympathetic neurons. J Neurochem 78(2): 298-303. 
Brunet, A., S. R. Datta and M. E. Greenberg (2001). Transcription-dependent and -
independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr 
Opin Neurobiol 11(3): 297-305. 
Burdeinick-Kerr, R., D. Govindarajan and D. E. Griffin (2009). Noncytolytic clearance of 
sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT 
signaling. J Virology 83(8): 3429-3435. 
 109 
 
Buss, R. R., W. Sun and R. W. Oppenheim (2006). Adaptive roles of programmed cell death 
during nervous system development. Annu Rev Neurosci 29: 1-35. 
Cain, K., S. B. Bratton and G. M. Cohen (2002). The Apaf-1 apoptosome: a large caspase-
activating complex. Biochimie 84(2-3): 203-214. 
Cameron, J. S., L. Alexopoulou, J. A. Sloane, A. B. DiBernardo, Y. Ma, B. Kosaras, R. Flavell, S. 
M. Strittmatter, J. Volpe, R. Sidman and T. Vartanian (2007). Toll-like receptor 3 is a 
potent negative regulator of axonal growth in mammals. J Neurosci 27(47): 13033-
13041. 
Carson, D. A. and J. M. Ribeiro (1993). Apoptosis and disease. Lancet 341(8855): 1251-1254. 
Cecconi, F., G. Alvarez-Bolado, B. I. Meyer, K. A. Roth and P. Gruss (1998). Apaf1 (CED-4 
homolog) regulates programmed cell death in mammalian development. Cell 94(6): 
727-737. 
Ceco, E. and E. M. McNally (2013). Modifying muscular dystrophy through transforming 
growth factor-beta. FEBS J 280(17): 4198-4209. 
Chang, C. M. and C. C. Chao (2013). Protein kinase CK2 enhances Mcl-1 gene expression 
through the serum response factor-mediated pathway in the rat hippocampus. J 
Neurosci Res 91(6): 808-817. 
Chang, J. Y., D. P. Martin and E. M. Johnson, Jr. (1990). Interferon suppresses sympathetic 
neuronal cell death caused by nerve growth factor deprivation. J Neurochem 55(2): 
436-445. 
Chao, D. T. and S. J. Korsmeyer (1998). BCL-2 family: regulators of cell death. Annu Rev 
Immunol 16: 395-419. 
Chawla-Sarkar, M., D. Lindner, Y. F. Liu, B. Williams, G. Sen, R. Silverman and E. Borden 
(2003). Apoptosis and interferons: role of interferon-stimulated genes as mediators 
of apoptosis. Apoptosis 8(3): 237-249. 
Chen, Y., Y. Ai, J. R. Slevin, B. E. Maley and D. M. Gash (2005). Progenitor proliferation in the 
adult hippocampus and substantia nigra induced by glial cell line-derived 
neurotrophic factor. Exp Neurol 196(1): 87-95. 
Chipuk, J. E. and D. R. Green (2008). How do BCL-2 proteins induce mitochondrial outer 
membrane permeabilization? Trends Cell Biol 18(4): 157-164. 
Cho, Y. J., A. Tsherniak, P. Tamayo, S. Santagata, A. Ligon, H. Greulich, R. Berhoukim, V. 
Amani, L. Goumnerova, C. G. Eberhart, C. C. Lau, J. M. Olson, et al. (2011). 
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup 
that drives poor clinical outcome. J Clin Oncol 29(11): 1424-1430. 
 110 
 
Choi, C., J. Y. Park, J. Lee, J. H. Lim, E. C. Shin, Y. S. Ahn, C. H. Kim, S. J. Kim, J. D. Kim, I. S. 
Choi and I. H. Choi (1999). Fas ligand and Fas are expressed constitutively in human 
astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma. J 
Immunol 162(4): 1889-1895. 
Choubey, D. and R. Panchanathan (2008). Interferon-inducible Ifi200-family genes in 
systemic lupus erythematosus. Immunol Lett 119(1-2): 32-41. 
Clarke, P. G. and S. Clarke (1996). Nineteenth century research on naturally occurring cell 
death and related phenomena. Anat Embryol 193(2): 81-99. 
Clemens, M. J. (2003). Interferons and apoptosis. J Interferon Cytokine Res 23(6): 277-292. 
Cohen, H. Y., S. Lavu, K. J. Bitterman, B. Hekking, T. A. Imahiyerobo, C. Miller, R. Frye, H. 
Ploegh, B. M. Kessler and D. A. Sinclair (2004). Acetylation of the C terminus of Ku70 
by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13(5): 627-638. 
Conway, K. E., B. B. McConnell, C. E. Bowring, C. D. Donald, S. T. Warren and P. M. Vertino 
(2000). TMS1, a novel proapoptotic caspase recruitment domain protein, is a target 
of methylation-induced gene silencing in human breast cancers. Cancer Res 60(22): 
6236-6242. 
Cory, S. and J. M. Adams (2002). The Bcl2 family: regulators of the cellular life-or-death 
switch. Nat Rev Cancer 2(9): 647-656. 
Creagh, E. M., H. Conroy and S. J. Martin (2003). Caspase-activation pathways in apoptosis 
and immunity. Immunol Rev 193: 10-21. 
Dabiri, G., D. A. Tumbarello, C. E. Turner and L. Van de Water (2008). TGF-beta1 slows the 
growth of pathogenic myofibroblasts through a mechanism requiring the focal 
adhesion protein, Hic-5. J Invest Dermatol 128(2): 280-291. 
Dafny, N. and P. B. Yang (2005). Interferon and the central nervous system. Eur J Pharmacol 
523(1-3): 1-15. 
Danial, N. N. and S. J. Korsmeyer (2004). Cell death: critical control points. Cell 116(2): 205-
219. 
Das, A., N. L. Banik and S. K. Ray (2009). Molecular mechanisms of the combination of 
retinoid and interferon-gamma for inducing differentiation and increasing apoptosis 
in human glioblastoma T98G and U87MG cells. Neurochem Res 34(1): 87-101. 
Davidescu, M., M. Sciaccaluga, L. Macchioni, R. Angelini, P. Lopalco, M. G. Rambotti, R. 
Roberti, A. Corcelli, E. Castigli and L. Corazzi (2012). Bromopyruvate mediates 
autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma 
cells. J Bioenerg Biomembr 44(1): 51-60. 
 111 
 
Davies, A. M. (2003). Regulation of neuronal survival and death by extracellular signals 
during development. EMBO J 22(11): 2537-2545. 
Davis, B. K., H. Wen and J. P. Ting (2011). The inflammasome NLRs in immunity, 
inflammation, and associated diseases. Annu Rev Immunol 29: 707-735. 
Deckwerth, T. L., R. M. Easton, C. M. Knudson, S. J. Korsmeyer and E. M. Johnson, Jr. (1998). 
Placement of the BCL2 family member BAX in the death pathway of sympathetic 
neurons activated by trophic factor deprivation. Exp Neurol 152(1): 150-162. 
Dedoni, S., M. Olianas, A. Ingianni and P. Onali (2012). Type I interferons impair BDNF-
induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y 
neuroblastoma cells and mouse primary cortical neurons. J Neurochem 122(1): 58-
71. 
Deng, J., N. Carlson, K. Takeyama, P. Dal Cin, M. Shipp and A. Letai (2007). BH3 profiling 
identifies three distinct classes of apoptotic blocks to predict response to ABT-737 
and conventional chemotherapeutic agents. Cancer Cell 12(2): 171-185. 
Deshmukh, M., C. Du, X. Wang and E. M. Johnson, Jr. (2002). Exogenous smac induces 
competence and permits caspase activation in sympathetic neurons. J Neurosci 
22(18): 8018-8027. 
Deshmukh, M. and E. M. Johnson, Jr. (1997). Programmed cell death in neurons: focus on 
the pathway of nerve growth factor deprivation-induced death of sympathetic 
neurons. Mol Pharmacol 51(6): 897-906. 
Deshmukh, M. and E. M. Johnson, Jr. (1998). Evidence of a novel event during neuronal 
death: development of competence-to-die in response to cytoplasmic cytochrome c. 
Neuron 21(4): 695-705. 
Dijkmans, R., J. Van Damme, F. Cornette, H. Heremans and A. Billiau (1990). Bacterial 
lipopolysaccharide potentiates gamma interferon-induced cytotoxicity for normal 
mouse and rat fibroblasts. Infect Immun 58(1): 32-36. 
Drexler, S. K., L. Bonsignore, M. Masin, A. Tardivel, R. Jackstadt, H. Hermeking, P. Schneider, 
O. Gross, J. Tschopp and A. S. Yazdi (2012). Tissue-specific opposing functions of the 
inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. PNAS 
109(45): 18384-18389. 
Dumitru, R., V. Gama, B. M. Fagan, J. J. Bower, V. Swahari, L. H. Pevny and M. Deshmukh 
(2012). Human embryonic stem cells have constitutively active Bax at the Golgi and 
are primed to undergo rapid apoptosis. Mol Cell 46(5): 573-583. 
Duprez, L., E. Wirawan, T. Vanden Berghe and P. Vandenabeele (2009). Major cell death 
pathways at a glance. Microbes Infect 11(13): 1050-1062. 
 112 
 
Eckelman, B. P., G. S. Salvesen and F. L. Scott (2006). Human inhibitor of apoptosis proteins: 
why XIAP is the black sheep of the family. EMBO Rep 7(10): 988-994. 
Ellis, H. M. and H. R. Horvitz (1986). Genetic control of programmed cell death in the 
nematode C. elegans. Cell 44(6): 817-829. 
Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of 
a heterogeneous disease. Acta Neuropathol 120(3): 305-316. 
Erwig, L. P. and P. M. Henson (2007). Immunological consequences of apoptotic cell 
phagocytosis. Am J Pathol 171(1): 2-8. 
Eskes, R., S. Desagher, B. Antonsson and J. C. Martinou (2000). Bid induces the 
oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol 
Cell Biol 20(3): 929-935. 
Fadeel, B. and S. Orrenius (2005). Apoptosis: a basic biological phenomenon with wide-
ranging implications in human disease. J Intern Med 258(6): 479-517. 
Fattet, S., C. Haberler, P. Legoix, P. Varlet, A. Lellouch-Tubiana, S. Lair, E. Manie, M. A. 
Raquin, D. Bours, S. Carpentier, E. Barillot, J. Grill, et al. (2009). Beta-catenin status in 
paediatric medulloblastomas: correlation of immunohistochemical expression with 
mutational status, genetic profiles, and clinical characteristics. J Pathol 218(1): 86-
94. 
Fellay, C., D. Frappaz, M. Sunyach, E. Franceschi, A. Brandes and R. Stupp (2011). 
Medulloblastomas in adults: prognostic factors and lessons from paediatrics. Curr 
Opin Neurol 24(6): 626-632. 
Fernandes-Alnemri, T., J. W. Yu, P. Datta, J. Wu and E. S. Alnemri (2009). AIM2 activates the 
inflammasome and cell death in response to cytoplasmic DNA. Nature 458(7237): 
509-513. 
Fink, S. L. and B. T. Cookson (2005). Apoptosis, pyroptosis, and necrosis: mechanistic 
description of dead and dying eukaryotic cells. Infect Immun 73(4): 1907-1916. 
Franchi, L., T. Eigenbrod, R. Munoz-Planillo and G. Nunez (2009). The inflammasome: a 
caspase-1-activation platform that regulates immune responses and disease 
pathogenesis. Nature Immunol 10(3): 241-247. 
Geiger, K., E. L. Howes and N. Sarvetnick (1994). Ectopic expression of gamma interferon in 
the eye protects transgenic mice from intraocular herpes simplex virus type 1 
infections. J Virol 68(9): 5556-5567. 
Geiger, K. D., M. S. Lee, C. Baugh and N. E. Sarvetnick (1995). Protective effects of 
interferon-gamma in intraocular herpes simplex type 1 infection do not depend on 
 113 
 
major histocompatibility complex class I or class II expression. J Neurovirol 1(5-6): 
405-409. 
Geiger, K. D., T. C. Nash, S. Sawyer, T. Krahl, G. Patstone, J. C. Reed, S. Krajewski, D. Dalton, 
M. J. Buchmeier and N. Sarvetnick (1997). Interferon-gamma protects against herpes 
simplex virus type 1-mediated neuronal death. Virology 238(2): 189-197. 
Ghiringhelli, F., L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. 
Panaretakis, G. Mignot, E. Ullrich, J. L. Perfettini, F. Schlemmer, et al. (2009). 
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent 
adaptive immunity against tumors. Nat Med 15(10): 1170-1178. 
Gibson, P., Y. Tong, G. Robinson, M. C. Thompson, D. S. Currle, C. Eden, T. A. Kranenburg, T. 
Hogg, H. Poppleton, J. Martin, D. Finkelstein, S. Pounds, et al. (2010). Subtypes of 
medulloblastoma have distinct developmental origins. Nature 468(7327): 1095-
1099. 
Gilbertson, R. J. and D. W. Ellison (2008). The origins of medulloblastoma subtypes. Annu 
Rev Pathol 3: 341-365. 
Glebova, N. O. and D. D. Ginty (2005). Growth and survival signals controlling sympathetic 
nervous system development. Annu Rev Neurosci 28: 191-222. 
Gorman, A. M. (2008). Neuronal cell death in neurodegenerative diseases: recurring themes 
around protein handling. J Cell Mol Med 12(6A): 2263-2280. 
Green, D. R. and G. I. Evan (2002). A matter of life and death. Cancer Cell 1(1): 19-30. 
Grinberg, M., R. Sarig, Y. Zaltsman, D. Frumkin, N. Grammatikakis, E. Reuveny and A. Gross 
(2002). tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis. 
J Biol Chem 277(14): 12237-12245. 
Guan, X., J. Sagara, T. Yokoyama, Y. Koganehira, M. Oguchi, T. Saida and S. Taniguchi (2003). 
ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant 
methylation in human melanoma. Int J Cancer 107(2): 202-208. 
Gysemans, C., H. Callewaert, L. Overbergh and C. Mathieu (2008). Cytokine signalling in the 
beta-cell: a dual role for IFNgamma. Biochem Soc Trans 36(Pt 3): 328-333. 
Hallahan, A. R., J. I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B. A. Hatton, T. L. Russell, R. 
G. Ellenbogen, I. D. Bernstein, P. A. Beachy and J. M. Olson (2004). The SmoA1 
mouse model reveals that notch signaling is critical for the growth and survival of 
sonic hedgehog-induced medulloblastomas. Cancer Res 64(21): 7794-7800. 
Hara, H., K. Fink, M. Endres, R. M. Friedlander, V. Gagliardini, J. Yuan and M. A. Moskowitz 
(1997). Attenuation of transient focal cerebral ischemic injury in transgenic mice 
 114 
 
expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab 17(4): 370-
375. 
Hara, H., R. M. Friedlander, V. Gagliardini, C. Ayata, K. Fink, Z. Huang, M. Shimizu-Sasamata, 
J. Yuan and M. A. Moskowitz (1997). Inhibition of interleukin 1beta converting 
enzyme family proteases reduces ischemic and excitotoxic neuronal damage. PNAS 
94(5): 2007-2012. 
Hatten, M. and M. Roussel (2011). Development and cancer of the cerebellum. Trends 
Neurosc 34(3): 134-142. 
Hatten, M. E. and N. Heintz (1995). Mechanisms of neural patterning and specification in 
the developing cerebellum. Annu Rev Neurosci 18: 385-408. 
Haugen, P. K. and P. C. Letourneau (1990). Interleukin-2 enhances chick and rat 
sympathetic, but not sensory, neurite outgrowth. J Neurosci Res 25(4): 443-452. 
Hengartner, M. O. (2000). The biochemistry of apoptosis. Nature 407(6805): 770-776. 
Hengartner, M. O., R. E. Ellis and H. R. Horvitz (1992). Caenorhabditis elegans gene ced-9 
protects cells from programmed cell death. Nature 356(6369): 494-499. 
Hengartner, M. O. and H. R. Horvitz (1994). C. elegans cell survival gene ced-9 encodes a 
functional homolog of the mammalian proto-oncogene bcl-2. Cell 76(4): 665-676. 
Hervas-Stubbs, S., J. L. Perez-Gracia, A. Rouzaut, M. F. Sanmamed, A. Le Bon and I. Melero 
(2011). Direct effects of type I interferons on cells of the immune system. Clin Cancer 
Res 17(9): 2619-2627. 
Honda, H. M. and P. Ping (2006). Mitochondrial permeability transition in cardiac cell injury 
and death. Cardiovasc Drugs Ther 20(6): 425-432. 
Hong, S., I. Hwang, Y. S. Lee, S. Park, W. K. Lee, T. Fernandes-Alnemri, E. S. Alnemri, Y. S. Kim 
and J. W. Yu (2013). Restoration of ASC expression sensitizes colorectal cancer cells 
to genotoxic stress-induced caspase-independent cell death. Cancer Lett 331(2): 
183-191. 
Honig, L. S. and R. N. Rosenberg (2000). Apoptosis and neurologic disease. Am J Med 108(4): 
317-330. 
Ippagunta, S. K., D. D. Brand, J. Luo, K. L. Boyd, C. Calabrese, R. Stienstra, F. L. Van de 
Veerdonk, M. G. Netea, L. A. Joosten, M. Lamkanfi and T. D. Kanneganti (2010). 
Inflammasome-independent role of apoptosis-associated speck-like protein 
containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J 
Biol Chem 285(16): 12454-12462. 
 115 
 
Jeong, J., J. Mao, T. Tenzen, A. H. Kottmann and A. P. McMahon (2004). Hedgehog signaling 
in the neural crest cells regulates the patterning and growth of facial primordia. 
Genes Dev 18(8): 937-951. 
Jones, D. T., N. Jager, M. Kool, T. Zichner, B. Hutter, M. Sultan, Y. J. Cho, T. J. Pugh, V. 
Hovestadt, A. M. Stutz, T. Rausch, H. J. Warnatz, et al. (2012). Dissecting the genomic 
complexity underlying medulloblastoma. Nature 488(7409): 100-105. 
Jung, J. E., G. S. Kim, H. Chen, C. M. Maier, P. Narasimhan, Y. S. Song, K. Niizuma, M. Katsu, 
N. Okami, H. Yoshioka, H. Sakata, C. E. Goeders, et al. (2010). Reperfusion and 
neurovascular dysfunction in stroke: from basic mechanisms to potential strategies 
for neuroprotection. Mol Neurobiol 41(2-3): 172-179. 
Kalvakolanu, D. V. and S. K. Roy (2005). CCAAT/enhancer binding proteins and interferon 
signaling pathways. J Interferon Cytokine Res 25(12): 757-769. 
Kamerman, P. R., P. J. Moss, J. Weber, V. C. Wallace, A. S. Rice and W. Huang (2012). 
Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in 
vitro experimental models. J Peripher Nerv Syst 17(1): 19-31. 
Katsuno, Y., S. Lamouille and R. Derynck (2013). TGF-beta signaling and epithelial-
mesenchymal transition in cancer progression. Curr Opin Oncol 25(1): 76-84. 
Kerr, J. F., A. H. Wyllie and A. R. Currie (1972). Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br J Cancer 26(4): 239-257. 
Kim, I. J., H. N. Beck, P. J. Lein and D. Higgins (2002). Interferon gamma induces retrograde 
dendritic retraction and inhibits synapse formation. J Neurosci 22(11): 4530-4539. 
Koirala, J., A. Adamski, L. Koch, D. Stueber, M. El-Azizi, N. M. Khardori, M. Ghassemi and R. 
M. Novak (2008). Interferon-gamma receptors in HIV-1 infection. AIDS Res Hum 
Retroviruses 24(8): 1097-1102. 
Kole, A. J., V. Swahari, S. M. Hammond and M. Deshmukh (2011). miR-29b is activated 
during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes 
Dev 25(2): 125-130. 
Kolly, L., M. Karababa, L. A. Joosten, S. Narayan, R. Salvi, V. Petrilli, J. Tschopp, W. B. van den 
Berg, A. K. So and N. Busso (2009). Inflammatory role of ASC in antigen-induced 
arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol 183(6): 4003-
4012. 
Kool, M., J. Koster, J. Bunt, N. E. Hasselt, A. Lakeman, P. van Sluis, D. Troost, N. S. Meeteren, 
H. N. Caron, J. Cloos, A. Mrsic, B. Ylstra, et al. (2008). Integrated genomics identifies 
five medulloblastoma subtypes with distinct genetic profiles, pathway signatures 
and clinicopathological features. PLoS One 3(8): e3088. 
 116 
 
Kostic, V., V. Jackson-Lewis, F. de Bilbao, M. Dubois-Dauphin and S. Przedborski (1997). Bcl-
2: prolonging life in a transgenic mouse model of familial amyotrophic lateral 
sclerosis. Science 277(5325): 559-562. 
Koul, D., R. Lapushin, H. J. Xu, G. B. Mills, J. U. Gutterman and D. Choubey (1998). p202 
prevents apoptosis in murine AKR-2B fibroblasts. Biochem Biophys Res Commun 
247(2): 379-382. 
Kuida, K., T. F. Haydar, C. Y. Kuan, Y. Gu, C. Taya, H. Karasuyama, M. S. Su, P. Rakic and R. A. 
Flavell (1998). Reduced apoptosis and cytochrome c-mediated caspase activation in 
mice lacking caspase 9. Cell 94(3): 325-337. 
Kuida, K., T. S. Zheng, S. Na, C. Kuan, D. Yang, H. Karasuyama, P. Rakic and R. A. Flavell 
(1996). Decreased apoptosis in the brain and premature lethality in CPP32-deficient 
mice. Nature 384(6607): 368-372. 
Lamkanfi, M., N. Festjens, W. Declercq, T. Vanden Berghe and P. Vandenabeele (2007). 
Caspases in cell survival, proliferation and differentiation. Cell Death Differ 14(1): 44-
55. 
Lau, J., C. Schmidt, S. L. Markant, M. D. Taylor, R. J. Wechsler-Reya and W. A. Weiss (2012). 
Matching mice to malignancy: molecular subgroups and models of 
medulloblastoma. Childs Nerv Syst 28(4): 521-532. 
Lei, K. and R. J. Davis (2003). JNK phosphorylation of Bim-related members of the Bcl2 
family induces Bax-dependent apoptosis. PNAS 100(5): 2432-2437. 
Letai, A., M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler and S. J. Korsmeyer (2002). 
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as 
prototype cancer therapeutics. Cancer Cell 2(3): 183-192. 
Levi-Montalcini, R. and B. Booker (1960). Destruction of the Sympathetic Ganglia in 
Mammals by an Antiserum to a Nerve-Growth Protein. PNAS 46(3): 384-391. 
Li, X., S. Taylor, B. Zegarelli, S. Shen, J. O'Rourke and R. E. Cone (2004). The induction of 
splenic suppressor T cells through an immune-privileged site requires an intact 
sympathetic nervous system. J Neuroimmunol 153(1-2): 40-49. 
Liu, W., Y. Luo, J. H. Dunn, D. A. Norris, C. A. Dinarello and M. Fujita (2013). Dual Role of 
Apoptosis-Associated Speck-Like Protein Containing a CARD (ASC) in Tumorigenesis 
of Human Melanoma. J Invest Dermatol 133(2): 518-527. 
Machida, E. O., M. V. Brock, C. M. Hooker, J. Nakayama, A. Ishida, J. Amano, M. A. Picchi, S. 
A. Belinsky, J. G. Herman, S. Taniguchi and S. B. Baylin (2006). Hypermethylation of 
ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 66(12): 6210-
6218. 
 117 
 
Madden, K. S., J. A. Moynihan, G. J. Brenner, S. Y. Felten, D. L. Felten and S. Livnat (1994). 
Sympathetic nervous system modulation of the immune system. III. Alterations in T 
and B cell proliferation and differentiation in vitro following chemical 
sympathectomy. J Neuroimmunol 49(1-2): 77-87. 
Maggirwar, S. B., P. D. Sarmiere, S. Dewhurst and R. S. Freeman (1998). Nerve growth 
factor-dependent activation of NF-kappaB contributes to survival of sympathetic 
neurons. J Neurosci 18(24): 10356-10365. 
Maher, S. G., A. L. Romero-Weaver, A. J. Scarzello and A. M. Gamero (2007). Interferon: 
cellular executioner or white knight? Curr Med Chem 14(12): 1279-1289. 
Mao, J., K. L. Ligon, E. Y. Rakhlin, S. P. Thayer, R. T. Bronson, D. Rowitch and A. P. McMahon 
(2006). A novel somatic mouse model to survey tumorigenic potential applied to the 
Hedgehog pathway. Cancer research 66(20): 10171-10178. 
Marino, S. (2005). Medulloblastoma: developmental mechanisms out of control. Trends Mol 
Med 11(1): 17-22. 
Marsden, V. S. and A. Strasser (2003). Control of apoptosis in the immune system: Bcl-2, 
BH3-only proteins and more. Annu Rev Immunol 21: 71-105. 
Martin, D. P., R. E. Schmidt, P. S. DiStefano, O. H. Lowry, J. G. Carter and E. M. Johnson, Jr. 
(1988). Inhibitors of protein synthesis and RNA synthesis prevent neuronal death 
caused by nerve growth factor deprivation. J Cell Biol 106(3): 829-844. 
Martin, G. S. (2003). Cell signaling and cancer. Cancer Cell 4(3): 167-174. 
Martinon, F. and J. Tschopp (2007). Inflammatory caspases and inflammasomes: master 
switches of inflammation. Cell Death Differ 14(1): 10-22. 
Marz, P., R. A. Gadient and U. Otten (1996). Expression of interleukin-6 receptor (IL-6R) and 
gp130 mRNA in PC12 cells and sympathetic neurons: modulation by tumor necrosis 
factor alpha (TNF-alpha). Brain Res 706(1): 71-79. 
Massague, J. (2008). TGFbeta in Cancer. Cell 134(2): 215-230. 
Milligan, C. E., D. Prevette, H. Yaginuma, S. Homma, C. Cardwell, L. C. Fritz, K. J. Tomaselli, R. 
W. Oppenheim and L. M. Schwartz (1995). Peptide inhibitors of the ICE protease 
family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron 
15(2): 385-393. 
Min, W., S. Ghosh and P. Lengyel (1996). The interferon-inducible p202 protein as a 
modulator of transcription: inhibition of NF-kappa B, c-Fos, and c-Jun activities. Mol 
Cell Biol 16(1): 359-368. 
 118 
 
Mir, M., V. J. Asensio, L. Tolosa, M. Gou-Fabregas, R. M. Soler, J. Llado and G. Olmos (2009). 
Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative 
stress and motoneuron death in rat spinal cord embryonic explants. Neuroscience 
162(4): 959-971. 
Mitchell, A. J., B. Yau, J. A. McQuillan, H. J. Ball, L. K. Too, A. Abtin, P. Hertzog, S. L. Leib, C. A. 
Jones, S. K. Gerega, W. Weninger and N. H. Hunt (2012). Inflammasome-dependent 
IFN-gamma drives pathogenesis in Streptococcus pneumoniae meningitis. J Immunol 
189(10): 4970-4980. 
Mondini, M., S. Costa, S. Sponza, F. Gugliesi, M. Gariglio and S. Landolfo (2010). The 
interferon-inducible HIN-200 gene family in apoptosis and inflammation: implication 
for autoimmunity. Autoimmunity 43(3): 226-231. 
Nakamura, T., D. H. Cho and S. A. Lipton (2012). Redox regulation of protein misfolding, 
mitochondrial dysfunction, synaptic damage, and cell death in neurodegenerative 
diseases. Exp Neurol 238(1): 12-21. 
Narayan, S., L. Kolly, A. So and N. Busso (2011). Increased interleukin-10 production by ASC-
deficient CD4+ T cells impairs bystander T-cell proliferation. Immunology 134(1): 33-
40. 
Nhan, T. Q., W. C. Liles and S. M. Schwartz (2006). Physiological functions of caspases 
beyond cell death. Am J Pathol 169(3): 729-737. 
Nishikawa, Y., M. Mishima, H. Nagasawa, I. Igarashi, K. Fujisaki, H. Otsuka and T. Mikami 
(2001). Interferon-gamma-induced apoptosis in host cells infected with Neospora 
caninum. Parasitology 123(Pt 1): 25-31. 
Northcott, P. A., D. J. Shih, J. Peacock, L. Garzia, A. S. Morrissy, T. Zichner, A. M. Stutz, A. 
Korshunov, J. Reimand, S. E. Schumacher, R. Beroukhim, D. W. Ellison, et al. (2012). 
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. 
Nature 488(7409): 49-56. 
Ohtsuka, T., X. F. Liu, Y. Koga, Y. Kitajima, Y. Nakafusa, C. W. Ha, S. W. Lee and K. Miyazaki 
(2006). Methylation-induced silencing of ASC and the effect of expressed ASC on 
p53-mediated chemosensitivity in colorectal cancer. Oncogene 25(12): 1807-1811. 
Ohtsuka, T., H. Ryu, Y. A. Minamishima, S. Macip, J. Sagara, K. I. Nakayama, S. A. Aaronson 
and S. W. Lee (2004). ASC is a Bax adaptor and regulates the p53-Bax mitochondrial 
apoptosis pathway. Nat Cell Biol 6(2): 121-128. 
Oppenheim, R. W. (1991). Cell death during development of the nervous system. Annu Rev 
Neurosci 14: 453-501. 
 119 
 
Ozoren, N. and W. S. El-Deiry (2003). Cell surface Death Receptor signaling in normal and 
cancer cells. Semin Cancer Biol 13(2): 135-147. 
Pardo, C. A., J. C. McArthur and J. W. Griffin (2001). HIV neuropathy: insights in the 
pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 6(1): 21-27. 
Parsons, M. J., P. Patel, D. J. Brat, L. Colbert and P. M. Vertino (2009). Silencing of TMS1/ASC 
promotes resistance to anoikis in breast epithelial cells. Cancer Res 69(5): 1706-
1711. 
Parsons, M. J. and P. M. Vertino (2006). Dual role of TMS1/ASC in death receptor signaling. 
Oncogene 25(52): 6948-6958. 
Pokrovskaja, K., T. Panaretakis and D. Grander (2005). Alternative signaling pathways 
regulating type I interferon-induced apoptosis. J Interferon Cytokine Res 25(12): 799-
810. 
Polkinghorn, W. R. and N. J. Tarbell (2007). Medulloblastoma: tumorigenesis, current clinical 
paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4(5): 295-
304. 
Potts, P. R., S. Singh, M. Knezek, C. B. Thompson and M. Deshmukh (2003). Critical function 
of endogenous XIAP in regulating caspase activation during sympathetic neuronal 
apoptosis. J Cell Biol 163(4): 789-799. 
Prendes, M. A., A. Harris, B. M. Wirostko, A. L. Gerber and B. Siesky (2013). The role of 
transforming growth factor beta in glaucoma and the therapeutic implications. Br J 
Ophthalmol 97(6): 680-686. 
Putcha, G. V., C. A. Harris, K. L. Moulder, R. M. Easton, C. B. Thompson and E. M. Johnson, Jr. 
(2002). Intrinsic and extrinsic pathway signaling during neuronal apoptosis: lessons 
from the analysis of mutant mice. J Cell Biol 157(3): 441-453. 
Ramachandran, K., H. Miller, E. Gordian, C. Rocha-Lima and R. Singal (2010). Methylation-
mediated silencing of TMS1 in pancreatic cancer and its potential contribution to 
chemosensitivity. Anticancer Res 30(10): 3919-3925. 
Ren, D., H. C. Tu, H. Kim, G. X. Wang, G. R. Bean, O. Takeuchi, J. R. Jeffers, G. P. Zambetti, J. 
J. Hsieh and E. H. Cheng (2010). BID, BIM, and PUMA are essential for activation of 
the BAX- and BAK-dependent cell death program. Science 330(6009): 1390-1393. 
Rich, J. N. (2003). The role of transforming growth factor-beta in primary brain tumors. 
Front Biosci 8: e245-260. 
 120 
 
Richter, K., J. Hausmann and P. Staeheli (2009). Interferon-gamma prevents death of 
bystander neurons during CD8 T cell responses in the brain. Am J Pathol 174(5): 
1799-1807. 
Riedl, S. J., W. Li, Y. Chao, R. Schwarzenbacher and Y. Shi (2005). Structure of the apoptotic 
protease-activating factor 1 bound to ADP. Nature 434(7035): 926-933. 
Riedl, S. J. and Y. Shi (2004). Molecular mechanisms of caspase regulation during apoptosis. 
Nat Rev Mol Cell Biol 5(11): 897-907. 
Rios, I., R. Alvarez-Rodriguez, E. Marti and S. Pons (2004). Bmp2 antagonizes sonic 
hedgehog-mediated proliferation of cerebellar granule neurones through Smad5 
signalling. Development 131(13): 3159-3168. 
Rottenberg, M. and K. Kristensson (2002). Effects of interferon-gamma on neuronal 
infections. Viral Immunol 15(2): 247-260. 
Roussel, M. and M. Hatten (2011). Cerebellum development and medulloblastoma. Curr Top 
Dev Biol 94: 235-282. 
Rubin, L. L. (1997). Neuronal cell death: when, why and how. Br Med Bull 53(3): 617-631. 
Sato, T., D. Kotake, M. Hiratsuka and N. Hirasawa (2013). Enhancement of inflammatory 
protein expression and nuclear factor Kappab (NF-Kappab) activity by trichostatin A 
(TSA) in OP9 preadipocytes. PLoS One 8(3): e59702. 
Satoh, T., N. Kambe and H. Matsue (2013). NLRP3 activation induces ASC-dependent 
programmed necrotic cell death, which leads to neutrophilic inflammation. Cell 
Death Dis 4: e644. 
Schmitt, M. J., D. Philippidou, S. E. Reinsbach, C. Margue, A. Wienecke-Baldacchino, D. 
Nashan, I. Behrmann and S. Kreis (2012). Interferon-gamma-induced activation of 
Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor 
suppressing microRNA-29 family in melanoma cells. Cell Commun Signal 10(1): 41. 
Schroder, K., P. J. Hertzog, T. Ravasi and D. A. Hume (2004). Interferon-gamma: an overview 
of signals, mechanisms and functions. J Leukoc Biol 75(2): 163-189. 
Sedger, L. M., D. M. Shows, R. A. Blanton, J. J. Peschon, R. G. Goodwin, D. Cosman and S. R. 
Wiley (1999). IFN-gamma mediates a novel antiviral activity through dynamic 
modulation of TRAIL and TRAIL receptor expression. J Immunol 163(2): 920-926. 
Selznick, L. A., T. S. Zheng, R. A. Flavell, P. Rakic and K. A. Roth (2000). Amyloid beta-induced 
neuronal death is bax-dependent but caspase-independent. J Neuropathol Exp 
Neurol 59(4): 271-279. 
 121 
 
Sharma, R. K., P. Tuli, S. S. Makkar and A. Parashar (2009). End-of-skin grafts in syndactyly 
release: description of a new flap for web space resurfacing and primary closure of 
finger defects. Hand 4(1): 29-34. 
Shaw, P. J., J. R. Lukens, S. Burns, H. Chi, M. A. McGargill and T. D. Kanneganti (2010). 
Cutting edge: critical role for PYCARD/ASC in the development of experimental 
autoimmune encephalomyelitis. J Immunol 184(9): 4610-4614. 
Shibanuma, M., J. Mashimo, A. Mita, T. Kuroki and K. Nose (1993). Cloning from a mouse 
osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, 
one of which seems to encode a follistatin-related polypeptide. Eur J Biochem 
217(1): 13-19. 
Shibanuma, M. and K. Nose (1998). Forced expression of hic-5, a senescence-related gene, 
potentiates a differentiation process of RCT-1 cells induced by retinoic acid. Int J 
Biochem Cell Biol 30(1): 39-45. 
Siegel, R. M., F. K. Chan, H. J. Chun and M. J. Lenardo (2000). The multifaceted role of Fas 
signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1(6): 469-
474. 
Smith, J. A., R. Zhang, A. K. Varma, A. Das, S. K. Ray and N. L. Banik (2009). Estrogen partially 
down-regulates PTEN to prevent apoptosis in VSC4.1 motoneurons following 
exposure to IFN-gamma. Brain Res 1301: 163-170. 
Srinivasula, S. M., M. Ahmad, T. Fernandes-Alnemri and E. S. Alnemri (1998). Autoactivation 
of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1(7): 949-957. 
Stehlik, C., L. Fiorentino, A. Dorfleutner, J. M. Bruey, E. M. Ariza, J. Sagara and J. C. Reed 
(2002). The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in 
nuclear factor kappaB activation pathways. J Exp Med 196(12): 1605-1615. 
Stevens, B., N. J. Allen, L. E. Vazquez, G. R. Howell, K. S. Christopherson, N. Nouri, K. D. 
Micheva, A. K. Mehalow, A. D. Huberman, B. Stafford, A. Sher, A. M. Litke, et al. 
(2007). The classical complement cascade mediates CNS synapse elimination. Cell 
131(6): 1164-1178. 
Stone, A. R., W. Bobo, D. J. Brat, N. S. Devi, E. G. Van Meir and P. M. Vertino (2004). 
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am 
J Pathol 165(4): 1151-1161. 
Sun, Y. F., L. Y. Yu, M. Saarma and U. Arumae (2003). Mutational analysis of N-Bak reveals 
different structural requirements for antiapoptotic activity in neurons and 
proapoptotic activity in nonneuronal cells. Mol Cell Neurosci 23(1): 134-143. 
 122 
 
Taylor, R. C., S. P. Cullen and S. J. Martin (2008). Apoptosis: controlled demolition at the 
cellular level. Nat Rev Mol Cell Biol 9(3): 231-241. 
Thoenen, H. and D. Edgar (1985). Neurotrophic factors. Science 229(4710): 238-242. 
Thompson, M., C. Fuller, T. Hogg, J. Dalton, D. Finkelstein, C. Lau, M. Chintagumpala, A. 
Adesina, D. Ashley, S. Kellie, M. Taylor, T. Curran, et al. (2006). Genomics identifies 
medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin 
Oncol 24(12): 1924-1931. 
Thornberry, N. A. and Y. Lazebnik (1998). Caspases: enemies within. Science 281(5381): 
1312-1316. 
Tsukamoto, L. F. and R. W. Price (1982). Interferon protects neurons in culture infected with 
vesicular stomatitis and herpes simplex viruses. J Neurol Sci 56(1): 115-128. 
Uo, T., Y. Kinoshita and R. S. Morrison (2005). Neurons exclusively express N-Bak, a BH3 
domain-only Bak isoform that promotes neuronal apoptosis. J Biol Chem 280(10): 
9065-9073. 
Uwabe, K., M. Matsumoto and K. Nagata (2005). Monokine induced by interferon-gamma 
acts as a neurotrophic factor on PC12 cells and rat primary sympathetic neurons. J 
Biol Chem 280(40): 34268-34277. 
Vaughn, A. E. and M. Deshmukh (2007). Essential postmitochondrial function of p53 
uncovered in DNA damage-induced apoptosis in neurons. Cell Death Differ 14(5): 
973-981. 
Vaughn, A. E. and M. Deshmukh (2008). Glucose metabolism inhibits apoptosis in neurons 
and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 10(12): 1477-
1483. 
Vaux, D. L. and S. J. Korsmeyer (1999). Cell death in development. Cell 96(2): 245-254. 
Victorio, S. C., L. A. Havton and A. L. Oliveira (2010). Absence of IFNgamma expression 
induces neuronal degeneration in the spinal cord of adult mice. J Neuroinflammation 
7: 77. 
Vinken, P. and B. Bruyn, Eds. (1999). The Autonomic Nervous System. Handbook of Clinical 
Neurology. Amsterdam, Elsevier. 
Wang, S. and W. S. El-Deiry (2003). TRAIL and apoptosis induction by TNF-family death 
receptors. Oncogene 22(53): 8628-8633. 
 123 
 
Wolter, K. G., Y. T. Hsu, C. L. Smith, A. Nechushtan, X. G. Xi and R. J. Youle (1997). Movement 
of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139(5): 1281-
1292. 
Wright, K. M. and M. Deshmukh (2006). Restricting apoptosis for postmitotic cell survival 
and its relevance to cancer. Cell Cycle 5(15): 1616-1620. 
Wright, K. M., M. W. Linhoff, P. R. Potts and M. Deshmukh (2004). Decreased apoptosome 
activity with neuronal differentiation sets the threshold for strict IAP regulation of 
apoptosis. J Cell Biol 167(2): 303-313. 
Wright, K. M., M. I. Smith, L. Farrag and M. Deshmukh (2007). Chromatin modification of 
Apaf-1 restricts the apoptotic pathway in mature neurons. J Cell Biol 179(5): 825-
832. 
Wright, K. M., A. E. Vaughn and M. Deshmukh (2007). Apoptosome dependent caspase-3 
activation pathway is non-redundant and necessary for apoptosis in sympathetic 
neurons. Cell Death Differ 14(3): 625-633. 
Xia, Z., M. Dickens, J. Raingeaud, R. J. Davis and M. E. Greenberg (1995). Opposing effects of 
ERK and JNK-p38 MAP kinases on apoptosis. Science 270(5240): 1326-1331. 
Xie, J., M. Murone, S. M. Luoh, A. Ryan, Q. Gu, C. Zhang, J. M. Bonifas, C. W. Lam, M. Hynes, 
A. Goddard, A. Rosenthal, E. H. Epstein, Jr., et al. (1998). Activating Smoothened 
mutations in sporadic basal-cell carcinoma. Nature 391(6662): 90-92. 
Yakovlev, A. G., S. M. Knoblach, L. Fan, G. B. Fox, R. Goodnight and A. I. Faden (1997). 
Activation of CPP32-like caspases contributes to neuronal apoptosis and 
neurological dysfunction after traumatic brain injury. J Neurosci 17(19): 7415-7424. 
Yong, V. W., F. Giuliani, M. Xue, A. Bar-Or and L. M. Metz (2007). Experimental models of 
neuroprotection relevant to multiple sclerosis. Neurology 68(22 Suppl 3): S32-37; 
discussion S43-54. 
Yordy, B., N. Iijima, A. Huttner, D. Leib and A. Iwasaki (2012). A neuron-specific role for 
autophagy in antiviral defense against herpes simplex virus. Cell Host Microbe 12(3): 
334-345. 
Yu, J. and L. Zhang (2003). No PUMA, no death: implications for p53-dependent apoptosis. 
Cancer Cell 4(4): 248-249. 
Zaki, M. H., P. Vogel, M. Body-Malapel, M. Lamkanfi and T.-D. Kanneganti (2010). IL-18 
production downstream of the Nlrp3 inflammasome confers protection against 
colorectal tumor formation. J Immunology 185(8): 4912-4920. 
 124 
 
Zhang, R., N. L. Banik and S. K. Ray (2008). Combination of all-trans retinoic acid and 
interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell 
cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 
(PTEN-proficient) and U87MG (PTEN-deficient) cells. Cancer Chemother Pharmacol 
62(3): 407-416. 
Zhou, Y., L. Ye, Q. Wan, L. Zhou, X. Wang, J. Li, S. Hu, D. Zhou and W. Ho (2009). Activation 
of Toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal 
cells. J Neurosci Res 87(13): 2916-2925. 
 
 
